


A RAY OF HOPE


ANNUAL REPORT TWENTY EIGHTEEN



Shaukat Khanum Memorial Cancer Hospital and Research Centre

A modern hospital
that provides
state-of-the-art cancer
treatment facilities
and services,
irrespective of the
patient's ability to pay.





**Shaukat Khanum Memorial Cancer
Hospital & Research Centre**

CONTENTS

ABOUT US

- 08 Mission
- 10 Chairman's Message
- 11 CEO's Message
- 13 Board of Governors
- 14 Governance Highlights
- 15 Senior Management
- 16 Our Story
- 19 Awards & Recognitions

PROJECTS & SERVICES

- 22 Clinical Activity 2018
- 24 Projects of SKMT
- 25 Revenue Break-up 2018
- 26 Philanthropic Spending
- 26 Top Cancers Seen at Our Hospitals
- 27 Survivor Story: Karzil
- 28 Patient Care
- 30 Survivor Story: Waleed
- 32 Nursing Care

RESEARCH & PUBLICATIONS

- 36 Basic Science Research Laboratory
- 38 Clinical Research Office
- 40 Cancer Registry and Clinical Data Management
- 42 Medical Publications

HIGHLIGHTS

- 50 SKMCH&RC, Lahore: Our Journey Towards Joint Commission International Accreditation
- 53 Pain Management Service Commences at SKMCH&RC, Peshawar
- 53 Emergency Assessment Room Expansion at SKMCH&RC, Lahore

DONATION PROGRAMMES

- 56** Zakat
- 57** Monthly Donation
- 58** Sponsorship of Equipment
- 59** Sponsorship of Projects
- 60** Founding Donor
- 61** Sponsor a Cancer Patient
- 62** Donate a Meal

FINANCIAL REPORTS

- 66** 5 Years Performance at a Glance
- 67** 5 Year Position at a Glance
- 68** Auditor's Report

CONTACT INFORMATION

- 110** Regional Offices
- 110** Overseas Offices
- 111** Walk-in Clinics
- 112** Laboratory Collection Centre

MISSION

“To act as a model institution to alleviate the suffering of patients with cancer through the application of modern methods of curative and palliative therapy irrespective of their ability to pay, the education of health care professionals and the public and perform research into the causes and treatment of cancer.”







“Congratulations to all the supporters, for SKMCH&RC in Lahore is the only charity hospital in Pakistan that has been awarded Hospital Accreditation from the Joint Commission International”

CHAIRMAN'S MESSAGE

Dear Friends,

The Shaukat Khanum Memorial Cancer Hospital and Research Centres in Lahore and Peshawar continue to be a ray of hope for patients suffering from cancer, irrespective of their ability to pay.

Today, it fills me with pride to see that our Hospitals set the standard for cancer treatment in Pakistan. The Shaukat Khanum Memorial Trust has succeeded in empowering the most qualified health care professionals with state-of-the-art technology and advanced diagnostic and therapeutic methods. Since inception, nearly 75% of our patients have continued to receive financially supported treatment. Our first Hospital in Lahore received the Gold Seal of Approval® by the Joint Commission International (JCI) in 2018. Congratulations to all the supporters, for we are the only charity hospital in Pakistan to have achieved this exacting approval, a testament to the fact that we are providing patient care of international standards.

Over the years, my faith in the goodness of mankind has increased greatly. Shaukat Khanum Memorial Cancer Hospital is indeed a living tribute to your kindness and generosity. We have now embarked on the construction of Pakistan's third and largest Shaukat Khanum Memorial Cancer Hospital and Research Centre in Karachi, which will be of enormous benefit not only to the most populous city of the country, but also to the people of the whole of Sindh as well as to those in Baluchistan. I hope you continue to contribute generously and help us in achieving our collective mission of fighting cancer.

With warmest regards,

Imran Khan
Chairman
Shaukat Khanum Memorial Trust

“The commitment of our supporters present around the world gives us confidence to continue to expand our life-saving mission.”



CEO'S MESSAGE

Dear Friends,

According to the latest reports by World Health Organization (WHO) on the global cancer burden in 2018, there were about 170,000 new cases of cancer in Pakistan. Worldwide, the cancer incidence rate is expected to rise by about 62 percent over the next two decades. The toll of cancer is greater especially in low and middle-income countries such as Pakistan. Shaukat Khanum Memorial Trust, having specialized cancer hospitals with all the diagnostic and therapeutic facilities under one roof, is determined to meet the upcoming challenges by increasing its capacity and expanding its outreach while staying at the forefront of cancer care in the region.

The increasing burden of cancer in the region compounded with our capacity constraints mean we have to not only prudently manage our existing resources but also enhance our capacity. In anticipation of these future challenges, we have planned a number of expansion projects that will enable us to help more people suffering from cancer. The expansion projects include building Pakistan's largest cancer hospital in Karachi; the construction work for it is expected to be completed within a three-year time frame, and a new Clinical Tower at Shaukat Khanum Memorial Cancer Hospital and Research Centre in Lahore, which will lead to doubling of clinical work area.

Along with the construction of new hospitals, our expanding network of Diagnostic Centres and Laboratory Collection Centres all across Pakistan is testament to our commitment to bring cancer diagnostic and therapeutic facilities closer to the patients' homes. Serving more cancer patients would not be possible without the help of a team of highly skilled professionals. Therefore, we are not only welcoming more healthcare professional but we are also providing training and education opportunities to healthcare professionals through a range of post graduate and graduate training programmes.

We remain committed to being at the cutting edge of cancer diagnosis and treatment, and to this end, have continued to invest in equipment, technology, medication, and research.



Researching into causes and treatment of cancer forms an integral part of the Hospital's mission. In the year 2018, as in the previous years, we published a number of peer-reviewed articles in major peer reviewed PubMed indexed journals.

Creating public awareness about early diagnosis and prevention of cancer plays an important role in fight against cancer. Our public awareness campaigns, including the annual breast cancer awareness and anti-smoking campaigns have expanded in outreach, online as well as on the ground.

In April 2018, SKMCH&RC, Lahore, received the Gold Seal of quality accreditation from the Joint Commission International. As this report goes to press, we are hard at work preparing for a similar accreditation survey at SKMCH&RC, Peshawar. In the year 2018, we needed Rs. 11 billion to support the two existing state-of-the-art cancer centres in Lahore and Peshawar and to embark upon the construction of the Hospital in Karachi and a new Clinical Tower in Lahore. These are ambitious goals but the commitment of our supporters present around the world gives us confidence to continue to expand our life-saving mission of providing cancer treatment to patients irrespective of their ability to pay. Once again, we look up to your support and belief in the value of life of those who are suffering from cancer.

Sincerely,

Dr. Faisal Sultan
Chief Executive Officer
Shaukat Khanum Memorial Cancer Hospital and Research Centre

BOARD OF GOVERNORS

The Board of Governors of SKMT serve in honorary capacity. The Board comprises of eminent individuals from diverse backgrounds, including bankers, researchers, businessmen, and physicians, who bring valuable experience to the table. The role of the Board includes governance and oversight of the clinical programmes, finances, and resource generation. The following Board Members served in the year 2018:

Mr. Imran Ahmed Khan Niazi
Chairman

Mr. Sheikh Muhammad Muneer

Dr. Nausherwan Khan Burki

Mr. Munir Kamal

Mrs. Aleema Khanum

Mr. Irfan Mustafa

Dr. Uzma Khan

Mr. Shahid Hafeez Kardar

Mr. Ashiq Hussain Qureshi

Mr. Tariq Shafi

Mr. Saifuddin Zoomkawala

Mr. Ehsan Mani

GOVERNANCE HIGHLIGHTS

The Shaukat Khanum Memorial Trust is committed to uphold requirements of the laws and emerging trends of corporate governance and supports a culture of ethical values.

BOARD COMPOSITION

- There are 12 members of the Board of which 10 are male and 2 are female.
- All members of the Board of Governors serve in honorary capacity.

CODE OF CONDUCT

The Trust has prepared a Code of Conduct and has ensured that appropriate steps have been taken to disseminate it throughout the organization along with its supporting policies and procedures.

MISSION STATEMENT AND POLICIES

The Board has developed a mission statement, overall strategy and significant policies of the Trust. A complete record of particulars of significant policies along with the dates on which they were approved or amended has been maintained.

DECISIONS BY THE BOARD

All the powers of the Board have been duly exercised and decisions on relevant matters have been taken by Board.

MEETINGS OF THE BOARD

There were 4 meetings of the Board during the year 2018 and all of them were presided over by the Chairman of the Board. Minutes of the meetings were duly recorded and circulated.

REMUNERATION

No remuneration is paid to any member of the Board of Governors. All members of the Board of Governors serve in honorary capacity.

ENDORSEMENT OF FINANCIAL STATEMENTS

CFO and CEO have duly endorsed the financial statements before approval of the Board.

COMMITTEES OF THE BOARD

The Board has formed following committees

- Audit Committee
- Investment Committee

The terms of reference of the aforesaid committees have been formed, documented and advised to the committees for compliance.

Meetings of the aforementioned committees are held before each quarterly meeting of the Board.

INTERNAL AUDIT FUNCTION

The Board has outsourced the internal audit function to BDO Ebrahim & Co. Chartered Accountants who are considered suitably qualified and experienced for the purpose and are conversant with the policies and procedures of the Trust.

EXTERNAL AUDITORS

A. F. Ferguson & Co Chartered Accountants are honorary auditors of the Trust. The auditors have been given a satisfactory rating under the quality control review program of the ICAP.

SENIOR MANAGEMENT

Our senior management team is committed to delivering state-of-the-art and holistic cancer care to its patients.



Dr. Faisal Sultan
Chief Executive Officer



Dr. Muhammed Aasim Yusuf
Chief Medical Officer



Mr. Muhammad Tahir Aziz
Chief Operating Officer
SKMCH&RC - Peshawar



Dr. Asif Loya
Medical Director
SKMCH&RC - Lahore



Mr. Tariq Azam
Director Marketing and
Resource Development



Ms. Tasnim Beg
Chief Financial Officer

OUR STORY

Shaukat Khanum Memorial Cancer Hospital and Research Centres (SKMCH&RC) are state-of-the-art cancer centres located in Lahore and Peshawar, Pakistan. SKMCH&RC, Lahore was the very first project of the Shaukat Khanum Memorial Trust, which is a charitable organization established under the Societies Registration Act XXI of 1860 of Pakistan.

INSPIRATION FOR MAKING THE HOSPITAL

Shaukat Khanum Memorial Cancer Hospital and Research Centre is the brainchild of Pakistan's Cricket World Cup winning captain and now Prime Minister of Pakistan, Mr. Imran Khan. The inspiration to build the Hospital came after his mother, Mrs. Shaukat Khanum, succumbed to cancer in 1985. During his mother's illness, he also witnessed the plight of poor cancer patients in the hospitals of Pakistan and deeply felt the need for a specialized cancer centre in his country. Being a developing country, where the majority do not have access to even elementary health care facilities, cancer was considered the ultimate symbol of hopelessness and almost certain death. Prior to the establishment of Shaukat Khanum Memorial Cancer Hospital and Research Centre in Lahore, no specialised institution for the comprehensive treatment of cancer existed in Pakistan.



Imran Khan decided to embark upon the journey of realizing his dream of making cancer care accessible to the people of his country, regardless of their ability to pay. Hence, began the story of enduring love of a son for his mother and of the passion of a nation.

THE BEGINNING OF A GREAT JOURNEY

The first fundraising dinner in support of the project was held in 1988 in Dubai, while Imran Khan was there to play a cricket tournament. As the donations started coming in, he knew there was no turning back. After he returned to Pakistan, he gathered a team of eminent individuals belonging to diverse backgrounds and formed the Board of Governors of the newly established Shaukat Khanum Memorial Trust.

At the beginning, Imran Khan faced scepticism from friends as well as various experts in the field of medicine who told him his idea would only fail and end up hurting the reputation he had built over the years as a cricketer. The Board held a meeting with twenty of the top doctors in Lahore for advice on how to proceed and all, except one, said it was not a feasible project. The one doctor who said it was possible to make the Hospital, warned it would be impossible to run it with the goal of treating the poor free of cost due to the inherently expensive cancer treatment.



FUNDRAISING

After the first one and a half year of fundraising in 1990, when Imran Khan seemed to have exhausted all his resources, he turned to school children and launched a fundraising team of "Imran's Tigers". The Tigers ended up creating history. They stopped motorists at traffic lights and went from door to door to collect funds. They not only collected funds that enabled the construction of the Hospital but also created awareness among the public for the need of the nation's first cancer hospital.

Pakistan's win under Imran Khan's captaincy in the 1992 Cricket World Cup in Melbourne helped the fundraising efforts. However, by 1994, the project was still an uphill battle and at this point, donor fatigue had even exhausted the overseas Pakistanis. The Hospital was planned to open in 1994 but by the October of the same year, US \$ 4 million were still needed to materialize this plan.



It was only at this point that Imran Khan and his team decided to test the support of the ordinary Pakistanis. They set out on a successful Mass Contact Campaign which started from mid-November and lasted till 28 December, 1994. They toured twenty-nine cities and collected US \$ 5 million in six weeks from the ordinary people of Pakistan. In the mornings, Imran Khan would address school assemblies and in the evenings he would travel through the streets. The generosity of the people of Pakistan was truly inspiring. By the December of 1994, Imran Khan himself had given almost half of what he owned to the Hospital.

During the entire first phase of construction, over a million individual donors, from ordinary citizens to the rich and famous, donated everything from cash, jewellery, and other valuables, to help the first SKMCH&RC transform from a dream to a reality.

MASTER PLAN

Dr. Nausherwan K. Burki MB, PhD, FRCP, FCPS, FCCP developed the master plan for the Hospital in 1990, while he was Professor of Medicine at the University of Kentucky, USA. He oversaw the building of the Hospital, which was designed by Graham Rapp of Arrasmith, Judd & Rapp, Architects in Health Planning, Louisville, Kentucky, USA. Design details on site were handled by Messrs. Nayyar Ali Dada and Associates of Lahore. Local engineering was performed by Messrs. Progressive Consultants, Lahore.



Pakistan's first Shaukat Khanum Memorial Cancer Hospital and Research Centre, located in Johar Town in Lahore, is built on a 20 acre site. It was planned in three phases with the first one costing nearly US\$ 22 million; nearly 67 percent of the required budget came in the form of donations.

Dr. Burki remains the Chief Medical Advisor and Member, Board of Governors, continuing to be involved with program development, quality control, and recruitment of consultant staff, as well as Professor of Medicine at the University of Connecticut Health Center, in Farmington, Connecticut, USA.

INAUGURATION

Finally, against all odds, after the completion of the first phase of the Hospital, Shaukat Khanum Memorial Cancer Hospital and Research Centre opened its doors to patients on December 29, 1994. Setting a new trend in Pakistan, the Hospital was not inaugurated by a VIP but by a ten year old cancer patient named Sumera Yusuf.



SKMCH&RC TODAY

Withstanding the test of time, Pakistan's first SKMCH&RC, in Lahore is today staffed by highly competent professionals and has gone from strength to strength, treating thousands of patients over the years. Today, it stands as one of the best cancer centres in the world and it is proud to have earned Joint Commission International's Gold Seal of Approval® for Hospital Accreditation. It is a unique cancer centre which has been built and operated for almost twenty-five years as a result of the support of the public, and which has consistently treated over 75% of its patients completely free.



The Shaukat Khanum Memorial Trust aims to build a series of hospitals in various cities of Pakistan to bring cancer care closer to the patients. Since a quarter of the patients at SKMCH&RC, Lahore belonged to the Khyber Pakhtunkhwa (KPK) province of Pakistan, and adjoining areas, the second Hospital was inaugurated in Peshawar, the capital city of KPK, in 2015.

In December 2018, SKMCH&RC in Peshawar successfully completed the third year of its operations and services at the Hospital continue to be scaled-up. In conjunction with the chemotherapy facilities, inpatient beds, a fully equipped ICU, radiology and pathology facilities are also operational. In the summers of 2019, SKMCH&RC in Peshawar is planned to complete phase II of its development with the commencement of radiotherapy services at the Hospital. Following completion of phase III, which is expected to be in the autumn of 2020, SKMCH&RC Peshawar will be a complete, standalone tertiary care cancer facility with all cancer diagnostic and therapeutic facilities under one roof, just like SKMCH&RC in Lahore.



As thousands of poor cancer patients continue to suffer in Sindh and adjoining areas because they cannot afford to make repeated trips to SKMCH&RC in Lahore or Peshawar, the third SKMCH&RC is being built in Karachi. The construction of a comprehensive cancer centre in Karachi will not only provide state-of-the-art cancer care facilities to the people of Sindh and Baluchistan, but it will also help to enhance healthcare standards and to develop training and employment opportunities in the wider region as a whole.

The construction work at the site is planned to commence in 2019 and is expected to complete over a three-year time-frame with the Hospital planned to open as a fully-functional cancer hospital with all the essential clinical and support departments one would expect of a facility of this nature. SKMCH&RC in Karachi will, upon completion, have over one million square feet of constructed space, which is more than twice the size of the current hospital in Lahore and this will be Pakistan's largest cancer hospital.



With its presence in over sixty-five cities of Pakistan in the form of Hospitals, Diagnostic Centres, Walk-in-Clinics (cancer screening centres), and Laboratory Collection Centres, the Shaukat Khanum Memorial Trust has emerged as one of the most credible charities of Pakistan and has been recognized by the World Health Organization and the Human Rights Society of Pakistan for its contribution towards humanity.

AWARDS & RECOGNITIONS

For more than two decades, SKMCH&RC has been committed to the highest standards of patient care, education, and research. The Hospital's commitment has been recognized at both, national and international levels.

ACCREDITATION FROM JOINT COMMISSION INTERNATIONAL

Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore has earned Joint Commission International's Gold Seal of Approval® for Hospital Accreditation by demonstrating continuous compliance with its internationally-recognized standards. The Gold Seal of Approval® is a symbol of quality that reflects an organization's commitment to providing safe and effective patient care.



SKMCH&RC, Lahore underwent a rigorous on-site survey from April 23 to 27, 2018. During the survey, a team of Joint Commission International expert surveyors evaluated compliance with hospital standards related to a variety of areas, including the International Patient Safety Goals, patient assessment and care, anesthesia and surgical care, medication management, patient and family education, quality improvement, infection prevention and control, governance and leadership, facility management, staff qualifications and education, and information management.

PAKISTAN CENTRE FOR PHILANTHROPY CERTIFICATION (PCP)

SKMCH&RC, Lahore has been recently awarded the NPO Certification for meeting standards in the areas of internal governance, financial management, and programme delivery by the PCP in 2018. We have achieved the PCP certification renewal every three years since then.



INTERNATIONAL HOSPITAL FEDERATION (IHF) MEMBERSHIP CERTIFICATION

SKMCH&RC, Lahore has been awarded the Membership Certificate by International Hospital Federation (IHF) in 2018.







PROJECTS & SERVICES

CLINICAL ACTIVITY 2018




9,878

New registrations



1,737,270

Pharmacy
Dispensing



5,106,837

Pathology tests



165,776

Imaging studies



195

Beds
available





247,508
Outpatient visits



13,213
Admissions




47,669
Chemotherapy




15,779
Surgical procedures




64,737
Radiation treatments




PROJECTS OF SKMT ACROSS PAKISTAN



REVENUE BREAK-UP 2018




CANCER PATIENT VISITS TO THE HOSPITAL SUPPORTED VS SELF-PAYING




PHILANTHROPIC SPENDING

FINANCIAL SUPPORT PROVIDED 2017-2018 RS. IN BILLIONS



TOP CANCERS SEEN AT OUR HOSPITALS





“I truly admire the way the Hospital gives patients a reason to smile and enjoy life with the help of various patient-centric activities.”

- Karzil's Mother

SURVIVOR STORY: KARZIL

I never imagined that children could get cancer, until my six-year old daughter, Karzil, was diagnosed with cancer. It was during the summer vacations, after she had passed the exams for preparatory class when I noticed a swelling on Karzil's right leg. At first, I thought she had hurt herself while playing. However, after a week, the swelling had grown and we took her to a local hospital, where Karzil underwent surgery. The doctor told us she had cancer. Such news is devastating for any parent, but was exceptionally difficult for us because we had already seen a loved one lose the battle with cancer.

Karzil's grandmother had passed away four years ago. At the moment of our daughter's diagnosis, all the pain and suffering her grandmother had gone through, came rushing back to haunt us. I knew it would be difficult to explain to Karzil what was happening. We had to explain to her not only that she had cancer, which her grandmother had battled with, but also, that her story did not have to have the same unhappy ending.

We were advised to take her to Shaukat Khanum Memorial Cancer Hospital and Research Centre (SKMCH&RC), in Lahore and the first good piece of news was relayed to us as she underwent the early tests; that our daughter had been diagnosed at an early stage of bone cancer and therefore had a good chance of successfully fighting the disease. Karzil's treatment, which started in May, 2016 included chemotherapy, radiation therapy, and corrective surgery on her leg, so as to enable her to walk on both her feet. The Hospital has a child-friendly environment that greatly helped us in convincing Karzil to attend regularly for her appointments. Even before she fell ill, she had wanted to be a doctor. The Hospital's Schooling Programme ensured my daughter stayed in touch with her books and her dream was never interrupted by her illness. I truly admire the way the Hospital gives patients a reason to smile and enjoy life with the help of various patient-centric activities.

After the initial surgery, a bone was removed from Karzil's right leg, leaving her with a limp in one foot. Thankfully, after reconstructive surgery, Karzil can now walk on both her feet. She loved to wear shoes with heels and after her surgery, with tears welling up in her eyes, she asked me if she would ever be able to wear heels again. I hugged her and assured her that nothing else mattered as long as she was here to light up my world with her smile, with or without high heels!

Today, Karzil has defeated cancer and is on regular follow-up. She has returned to school and a long academic journey awaits her but all my prayers are with my daughter. May she be a kind and loving doctor, easing the pain of others, just like the doctors and other para medial staff at Shaukat Khanum Hospital.



PATIENT CARE

Shaukat Khanum Memorial Cancer Hospital and Research Centres located in Lahore and Peshawar continue to deliver cancer care in line with our mission statement. As the burden of cancer in Pakistan grows each year, we strive towards taking in as many new cancer patients as possible within our resources. In 2018, our system recorded more than 9,800 new patient registrations, which is nearly a 10 percent increase from the previous year.

We remain committed to being at the cutting edge of cancer diagnosis and treatment, and, to this end, a feather in our cap is accreditation by the Joint Commission International (JCI) in early 2018. JCI is an international body based in the United States that recognizes hospitals all over the world for quality in all aspects of their functioning. SKMCH&RC, Lahore has earned Joint Commission International's Gold Seal of Approval® for Hospital Accreditation by demonstrating continuous compliance with its internationally-recognized standards. The Gold Seal of Approval® is a symbol of quality that reflects an organization's commitment to providing safe and effective patient care.

We have continued to invest heavily in manpower, equipment, technology, medication and infrastructure. By the end of the year, 126 faculty members including consultants and senior instructors were available in all the departments of medical division providing highest quality of medical expertise to manage its ever-increasing cancer workload. These included 13 surgical oncologists, 9 consultant medical oncologists, 8 consultant paediatric oncologists and 7 clinical & radiation oncologists who have their core expertise in cancer care.

Bed strength in Lahore is 195 beds, including 11 Intensive Care Unit beds and 4 High Dependency Unit beds. Over 247,000 patients were seen in the Outpatient Department and 13,213 admissions were recorded, about 10 percent increase from the previous year. Approximately, 5.1 million pathology tests, 165,776 radiology tests and procedures, 64,737 radiation procedures and 15,779 surgical procedures were performed. 47,669 patients received chemotherapy and more than 1.6 million drugs (including the latest chemotherapeutic agents) were dispensed from pharmacy.

SKMCH&RC in Lahore currently has seven fully functional operation theatres along with an expanded Post Anaesthesia Care Unit (PACU). Plans are underway to start the eighth operation theatre in July 2019. Radiology

services at SKMCH&RC in Lahore will also be augmented with the addition of a futuristic 3 Tesla MRI, 160 slice CT scanner, a mammography unit, fluoroscopy machine and ultrasound units. Allogeneic bone marrow transplant (BMT) was launched in 2017 for paediatric patients and we are gearing towards treating our first adult allogeneic BMT patient in 2019.

SKMCH&RC in Peshawar is expected to complete phase II of development with the commencement of radiation oncology in the summer of 2019. The commissioning of two state of the art linear accelerators in Peshawar will make SKMCH&RC the largest radiation service provider in Pakistan with a total of 7 linear accelerators. Radiology services will also expand at SKMCH&RC, Peshawar with the addition of the latest MRI and CT scanners. A CT simulator and brachytherapy system will also be added in the radiation oncology department to cater to the ever-increasing demand for this service.

A network of almost 200 laboratory collection centres exists all around the country with a footprint of 65 cities all over Pakistan. These centres create a major inflow of samples into one of the most modern laboratory in the country, hence, playing an important role in revenue generation for the hospital, which goes towards the treatment of indigent cancer patients.

We continue to invest in medical education and offer postgraduate training programs recognized by the College of Physicians and Surgeons of Pakistan (CPSP). There are CPSP approved training programs available in radiation oncology, pathology, radiology, nuclear medicine, medical oncology, internal medicine, anaesthesia, pediatric oncology, surgical oncology, general surgery, hematology, gastroenterology, infectious diseases, pulmonology, oral and maxillofacial surgery, breast surgery and endocrinology. Additionally, diploma programs in pre-operative nursing, oncology cancer nursing and emergency/critical care nursing and medical laboratory technology are part of the hospital based training.



“At that moment, he knew if the little heart stops beating, his own heart would lose its rhythm forever. He redoubled his resolve to fight for his son.”

-Waleed's father



SURVIVOR STORY: WALEED

In the year 2014, Waleed Ahmed, a young six year old boy in Class 1 was living with his parents and two siblings in Kotri, Jamshoro (Sindh). He would impatiently wait each evening to hear the footsteps of his father, who worked as a salesperson at a local ice-cream company, so he could greet him with a big hug. Everyone knew that if Waleed is upset, his father knows the secret to cheer him up. However, even his father could not do the trick when Waleed started having fever that would not go away. At first, his condition was misdiagnosed at a local hospital as a chest infection. However, his parents were truly alarmed when they noticed a mass on Waleed's neck.

In search of a cure to what ailed their son, the family travelled to Chiniot city in Punjab, where Waleed's maternal grandparents lived and then to Faisalabad, where a local hospital operated on the mass and sent the sample to Shaukat Khanum Laboratory Collection Centre for analysis. When the results came back, Waleed was diagnosed with Hodgkin's Lymphoma (a type of cancer). At that moment, his parents felt utter hopelessness, as several questions started whirling around in their minds. Is the treatment even possible, how will they manage to cover the treatment cost even if the treatment is possible, will they lose their son? At that moment, they made a decision. They would do whatever it takes and travel any number of miles in order to save their little beloved boy.

They were advised to go to Karachi for treatment, as chemotherapy is a prolonged treatment and it would be convenient for them to be closer to their home. They visited the Shaukat Khanum Diagnostic Centre and Clinic in Karachi from where they were referred to SKMCH&RC, Lahore. This meant Waleed's father would have to leave his job for an uncertain period of time, part from his other children, and take into account traveling cost in addition to treat-

“Waleed Ahmed embodies the need for a specialized cancer centre in Sindh and he is an example that cancer is curable. On December 29, 2016, Waleed travelled with his father to the DHA City in Karachi to perform the ground-breaking of Pakistan's third SKMCH&RC, an ideal location that is easily accessible for people belonging to not only Sindh but also Baluchistan.”

ment cost. As they travelled to SKMCH&RC in Lahore, he was holding his son close to his heart. He focused on the rhythm that seemed to be perfectly in sync with his own heartbeat—as if an extension of his own heart. At that moment, he knew if the little heart stops beating, his own heart would lose its rhythm forever. He redoubled his resolve to fight for his son.

As they reached the Hospital, a wave of relief came over them. Waleed was not only accepted for treatment at SKMCH&RC but he was offered full financial support. At the Hospital, special care was taken to explain Waleed's diagnosis to his parents. They were glad to know that the Hospital houses a play-room for paediatric patients to divert their attention from the treatment. In addition, the Hospital's schooling programme provides the opportunity to patients such as Waleed to continue with their school course work, if they wish. For one year, the Hospital was like a home to them where a multidisciplinary team worked dedicatedly to treat Waleed.

Waleed proved to be a very brave boy who managed to defeat cancer owing to the constant support from his family and the team at the Hospital. Today, he is back in Hyderabad with his siblings, whom he dearly missed during his treatment. He loves to play cricket and football with just anyone who is able to throw a ball. His father recalls with amusement that when Waleed returned to school and the teacher asked the class to write a paragraph on 'how did you spend your holiday', and he wrote, "I beat cancer."

His father's heart swelled with pride as he witnessed the moment when his brave boy pushed the shovel into the ground—symbolizing the beginning of a new dawn of hope for people suffering from cancer in Sindh and Baluchistan.





NURSING CARE

Year 2018 was challenging as well as very exciting for the Nursing Division as this was the year when SKMCH&RC received a schedule for Joint Commission International Accreditation (JCIA) Survey to be conducted in the last week of April. All energies, efforts and resources were geared to develop, implement and maintain the standards of customary high quality and safe care provided to cancer patients. In light of the JCIA Manual 6th edition, all policies and procedures were reviewed and updated, and nursing staff was educated accordingly. The hard work and efforts of our Hospital's staff paid off when SKMCH&RC, Lahore received the Gold Seal of Approval by the Joint Commission International.


In 2018, we overcame the challenge of maintaining the nursing staff numbers that ensure optimal nursing care is available to all our patients by hiring a total 196 Registered Nurses, 94 Health Care Assistants, 2 Unit Coordinators and 28 Operating Room Technicians for SKMCH&RC, Lahore. Two Clinical Nurse managers were appointed for supervision of nursing services on weekends and public holidays. To combat the challenge of provision of trained staff for operating rooms, a new category of Surgical Technicians was introduced. 10 surgical technicians were hired and inducted to a 1- year certification program in Operating Room under a close supervision of Nursing Instructor. The Emergency Assessment Room (EAR) was segregated into Adult and Pediatric EAR. This extension led to the hiring and training of new nursing staff.

Nursing Division always strives for professional development and growth of nurses. This year, 10 nurses completed Diploma in Oncology Nursing, 5 nurses completed Diploma in Peri-operative Nursing and 5 nurses completed Diploma in Critical Care. All are promoted to Official Shift Leader positions and have returned to their specialized units for working. One Nursing Instructor has completed Master Degree from the University of POUP, two Clinical Nurse Managers completed a program of Certified Health Care Quality Professional (CHQP) and one Nursing Instructor proceeded for MScN at UOL.


The International Nurses Day was celebrated on May 12, 2018 at SKMCH&RC to mark the contributions of the nursing staff in delivering outstanding patient care. The annual sports festival was organized this year as well to aid in the physical and psychological wellness of our nursing staff.

A two-day nursing symposium was organized as part of the 17th Shaukat Khanum Cancer Symposium (SKCS) in November 2018 where a number of renowned national and international nurse scholars were invited to present their evidence based work.

DISTRIBUTION OF NURSING STAFF AT SKMCH&RC, LAHORE



DISTRIBUTION OF NURSING STAFF AT SKMCH&RC, PESHAWAR







**RESEARCH &
PUBLICATIONS**



“The study on Indoleamine 2,3 dioxygenase as an immunotherapeutic target brings new hope for cancer patients.”

RESEARCH

Shaukat Khanum Memorial Cancer Hospital and Research Centre (SKMCH&RC) is committed to perform research of highest scientific and ethical standards as reflected in our mission statement. The three main sections of our research division namely, the Basic Science Research Lab, Clinical Research Office, and Cancer Registry & Clinical Data Management are dedicated to perform and facilitate research in a number of ways.

A total of 66 manuscripts were published during 2018 in peer reviewed PubMed indexed journals. Six collaborative projects with grants from Norwegian Research Council, Pakistan Health Research Council, Glaxo Smith Klein and Highnoon Laboratories were conducted. SKMCH&RC is a part of four international trials in collaboration with Hoffman La Roche, Glaxo Smith Klein and London School of Hygiene and Tropical Medicine.



BASIC SCIENCE RESEARCH LABORATORY

The Basic Science Research Laboratory conducts research into the causes and treatment of cancer and through our translational research program, aim to find better ways to prevent cancer, diagnose at an early stage and to outline effective management plans.

Research program is directed towards exploring the contribution of breast cancer susceptibility genes to the occurrence of early-onset and familial breast and ovarian cancer in Pakistan, a country with one of the highest rates for these malignancies in Asia. The knowledge so gained leads to a better understanding of the causes of breast and ovarian cancer and contribute to the development of improved preventive, early detection and treatment strategies. The laboratory also works in collaboration with the Consortium of Investigators of Modifiers of BRCA1/2, and an Asian Breast Cancer consortium. Other ongoing genetic studies are about the contribution of genetic factors to colorectal and pancreatic cancers in Pakistan. Two other studies are about investigating the proteomic profiles of oral and colorectal cancer stem cells. These studies may enable to find markers linked with tumour metastasis. Studies are also conducted about immunosuppression marker in breast cancer progression and prognostic markers in chronic lymphocytic leukemia. In total, 5 research papers were published in peer-reviewed journals during this year.

SKMCH&RC's senior research scientist and his team published the mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations, in collaboration with an international team of leading researchers from 69 centers in 49 countries on 6 continents. SKMCH&RC is one of the major centers contributing substantial data from Asia. The data presented in this study provides new insight into the worldwide distribution of BRCA1/2 mutations. Knowledge of the population-specific mutational spectrum in BRCA1/2 could inform efficient strategies for genetic testing and may justify a more broad-based oncogenetic testing in some populations.

Partner and localizer of BRCA2 (PALB2) is a breast cancer susceptibility gene that plays an important role in breast cancer. The research paper on this is the first study assessing the contribution of PALB2 mutations to 370 early-onset and familial breast/ovarian cancer patients from Pakistan, all were negative for major breast cancer susceptibility genes (BRCA1, BRCA2, TP53, CHEK2, and RAD51C) mutations. 372 healthy controls were screened for the presence of the identified mutations. A novel disease-causative mutation was identified in one familial breast cancer patient. Besides, four potentially disease-causative mutations were identified in a familial bilateral breast cancer patient or in early-onset breast cancer patients. All five mutations were absent in 372 healthy controls suggesting that they are disease associated. Our findings show that PALB2 mutations account for a small proportion of early-onset and hereditary breast/ovarian cancer cases in Pakistan.

The study on Indoleamine 2,3 dioxygenase as an immunotherapeutic target brings new hope for cancer patients. IDO overexpression in various cancers is associated with poor prognosis. Several preclinical and clinical trials have been proceeding and recommend that IDO inhibitor maybe an influential tool against a wide range of cancers. IDO inhibitors as adjuvant therapeutic agents may also have clinical implications. Thus, IDO has potential to be used as an immunotherapeutic target.

SKMCH&RC researchers are taking part in cancer awareness campaigns, developing research infrastructure and building capacity by teaching, training and supervising masters and doctoral level programs in collaboration with national universities. Researchers enjoy fertile collaboration with our hospital-based specialty physicians and with other Pakistani institutions in Lahore (Lahore University of Management Sciences; the School of Biological Sciences, and the University of Health Sciences), and Karachi (Agha Khan University) and with those at international centers, including the German Cancer Research Centre in Heidelberg, the University of Bradford, UK and the Pomeranian Medical University, Szczecin, Poland.

“ Our senior research scientist and his team published the mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations, in collaboration with an international team of leading researchers from 69 centers in 49 countries on 6 continents ”





CLINICAL RESEARCH OFFICE

“ Our Clinical Research Office has established an efficient infrastructure and human resource pool that can facilitate robust conduct of clinical trials. We have one of the largest trained workforce for research in the country.”

The Clinical Research Office (CRO) continues to support researchers at SKMCH&RC in diverse ways. It provides up to date guidance on research procedures, thus helping to keep research practices well in line with international standards. It plays a vital role in maintaining research database, liaising with research collaborators and oversight bodies, and provides secretarial support to review bodies of SKM-CH&RC. Individual investigators are facilitated in developing their research plans, setting up their projects and in day-to-day research activities.

A key function of CRO is coordination of clinical trials. It has facilitated clinical trials in different phases in diverse therapeutic areas. Clinical trials are considered amongst most sophisticated research designs producing evidence of highest authority. With the clinical specialist serving as the main clinical lead, the Clinical Research Office plays a central role in clinical trials, throughout the research

life cycle. CRO comprises of a team of experienced research officers and administrators with post graduate qualifications in clinical trials, pharmacology and public health. Clinical research officers, well trained in good clinical practice guidelines and trial operations, are the main advocates of patients who participate in clinical trials and also liaise with clinical staff, funding bodies and regulatory bodies. Over time, CRO has established an efficient infrastructure and human resource pool that can facilitate robust conduct of clinical trials. Currently there are more than 100 members from the clinical teams including members from nursing, pharmacy, radiology, pathology, internal medicine and oncology, well trained in the international standards for the conduct of clinical trials, making us a site with one of the largest trained workforce for research in the country. In the year 2018, the Clinical Research Office was involved in three international multi-centre clinical trials. CRO has met the targets in these trials and this has led to SKMCH&RC being established as the preferred destination for clinical trials in the region.

Physician investigators of SKMCH&RC are enthusiastic to perform research into causes and treatments of cancer hence a large number of prospective studies and investigator initiated trials were initiated this year in the Hospital. In addition, the existing data has also been used increasingly to collect evidence to answer certain research questions.

Expertise, infrastructure and the research culture at SKMCH&RC has attracted new national and international collaborations. These collaborations are focusing on oncology (such as role of HPV in cervical cancer) as well as areas other than cancer like Diabetes Mellitus and Tuberculosis, a high priority area for Pakistan. Another focus of recent collaborations has been use of artificial intelligence for computerized profiling of histopathological and radiological features of various malignancies. Recent work has been done on automated scoring of histological features of oral cancer with University of Warwick, Coventry and Warwickshire Pathology services (CWPS), Warwick Medical School (WMS) & University Hospitals Coventry & Warwickshire (UHCW) NHS Trust and University of Sheffield, UK. Output from this project has been presented at the American Society of Clinical Oncology (ASCO) annual meeting, National Cancer Research Institute (NCRI) conference and at the International Symposium on Biomedical Imaging (ISBI'18). Other exciting research collaborations with Norwegian Council of Research and Pakistan Health Research Council are also being coordinated. As new collaborations have developed, the ones from the past have matured and are producing exciting results which are being published in peer reviewed journals.



The CRO is also involved in teaching and training activities related to research and research ethics both within and outside SKMCH&RC. The Clinical Research Office has developed a research oversight programme that facilitates researchers in ensuring responsible conduct of research for their respective studies. CRO also acts as the central repository for all research at the Hospital and is responsible for appropriate archival of all research records.

CRO team has had the privilege to represent SKMCH&RC at national and international conferences, symposia and research related meetings such as World Congress of Bioethics held at Bangalore, India and International Diabetes Federation (IDF) annual meeting. CRO team also successfully represented the Hospital at the fellowship organized by the Good Clinical Practice Alliance – Europe (GCPA) and the Strategic Initiative for Developing Capacity in Ethical Review (SIDCER) in cooperation with the Global Health Institute (GHI), University of Antwerp (GHI-UA), and the Middleton Foundation for Ethical Studies (MFES) and follow up collaborative liaison from this fellowship is ongoing. In addition, CRO team was part of the bioethics training initiative by the Centre of Biomedical Ethics and Culture (CBEC) and Kenya Medical Research Institute (KEMRI). This training initiative focused on research and public health ethics training and practicum for selected participants from Kenya and Pakistan.

To ensure that all research conducted at the Hospital is in accordance with international policies and the highest ethical standards, working guidelines include a well-defined selection and review process for all research activities. This process calls for a review by the Scientific Review Committee (SRC) for scientific validity followed by review of the study by the Institutional Review Board (IRB), which safeguards the well-being and rights of human subjects who participate in the research. The Institutional Review Board is composed of members from various walks of life with both external and internal members; the chairperson is always a non-SKMCH&RC individual to ensure unbiased review. Research office is also involved in providing secretarial support to the Hospital Ethics Committee, which acts as an advisory committee for ethical dilemmas encountered in clinical practice and creates awareness on ethical issues in healthcare within the Hospital via educational sessions and workshops.

Research at SKMCH&RC is believed to grow in years to come with main focus on capacity building and new partnerships.



“In the year 2018, a total of 6,851 neoplasms were added to the Registry database, of which 473 were benign and 6,378 malignant.”



CANCER REGISTRY AND CLINICAL DATA MANAGEMENT

The hospital-based cancer registry has been functioning since the inauguration of the Shaukat Khanum Memorial Cancer and Research Centre (SKMCH&RC) in Lahore in December 1994. Every year, the Registry generates cancer statistics according to sex, age, demographic area, topography, morphology, stage, grade, etc.

Patients included in this report include those registered at the facilities affiliated with the Shaukat Khanum Memorial Trust and accessioned into the computerized cancer registry within the Hospital Information System in Lahore. The facilities include two hospitals, SKMCH&RC in Lahore (since 1994) and SKMCH&RC in Peshawar (since 2015), and the Karachi Diagnostic Centre (since 2010).

During the last twenty-four years, a total of 96,832 neoplasms were registered at SKMCH&RC and KDC, of which 5,451 were benign and 91,381 malignant. The distributions seen among males and females were 48.3% and 51.7%, respectively. About 90.1% tumours were found in adults, whereas, 9.9% were diagnosed in children. Top three malignancies in all age-groups, both sexes combined were: breast cancer, leukaemia, and lip & oral cavity cancer. Top three malignancies among adult females were cancers of the breast, ovary & uterine adnexa, and lip & oral cavity, while, in adult males, prostate, colon, rectum, anal canal & anus, and lip & oral cavity cancers. In children, acute lymphoblastic leukaemia, Hodgkin lymphoma, and non-Hodgkin lymphoma (NHL) were recorded as the commonest malignancies.

In the year 2018, a total of 6,851 neoplasms were added to the Registry database, of which 473 were benign and 6,378 malignant. Of a total of 6,378 malignant cases, 6,244 (97.9%) were analytical cases, whereas, 134 (2.1%) were non-analytical cases. Class of Case 0 to 2 are considered analytical and 3 to 9 non-analytical cases, according to the Facility Oncology Revised Data Standards (2004). In the area of cancer registration, analytical cases are included in treatment and survival analysis, while non-analytical cases are usually not included in routine treatment or survival statistics.

In adult males, colon, rectum, anal canal & anus, prostate, and lip & oral cavity were the commonly diagnosed malignancies, whereas, in adult females, breast, cervix, and colon, rectum, anal canal & anus were the leading malignancies. In children, Hodgkin lymphoma, acute lymphoblastic leukemia, and non-Hodgkin lymphoma were the commonest malignancies.

The Registry uses the American Joint Committee on Cancer ((AJCC) 8th edition)), staging manual, for staging all available cancer sites. TNM categorizes cancers in stages 0, 1, 2, 3, 4, and also as unstageable and not applicable. Among 6,244 analytical cases, 0.6% cases were staged in Stage 0, 15.1% in Stage I, 25.8% in Stage II, 23.0% in Stage III, and 18.2% in Stage IV. In 11.8% of the patients, no AJCC stage was defined and 5.5% of the cases were unstageable.

According to the SEER Summary Staging Manual-2000 (Codes and Coding instructions), 0.6% cases were in situ, 20.5% localized, 40.9% regional, and 20.4% distant. In 17.6% of the cases, the summary stage was unknown.

By histological grading/differentiation/ immunophenotype, 6.4% presented in Grade I, 29.1% in Grade II, 21.2% in Grade III, 1.5% in Grade IV, 0.4% as T-cell, 6.1% as B-cell, and grade / differentiation / immunophenotype was not determined/not stated/not applicable in 35.3% of the cases.





MEDICAL PUBLICATIONS

Hassan A, Siddique M, Riaz S, Khan AI, Nawaz MK, Bashir H. Oct-Dec 2018. Medullary Thyroid Carcinoma: Prognostic Variables And Tumour Markers Affecting Survival. *J Ayub Med Coll Abbottabad*;30(Suppl 1)(4):S627-S632.

Rajput MSA et al. Dec 2018. Preservation of Hearing and Facial Nerve Function with the Microsurgical Excision of Large Vestibular Schwannomas: Experience with the Retrosigmoid Approach. *Cureus* 4;10(12):e3684. doi: 10.7759/cureus.3684.

Faisal M, Adeel M, Riaz S, Anwar A, Rashid A, Usman S, Jamshed A, Hussain R. Jul-Dec 2018. The Submental Island Flap in Head and Neck Cancer. *Ann Maxillofac Surg*;8(2):287-291.doi: 10.4103/ams.ams_225_18.

Asghar K, Loya A, Rana IA, Tahseen M, Ishaq M, Farooq A, Bakar MA, Masood I. Jan 2019. Indoleamine 2,3-dioxygenase expression and overall survival in patients diagnosed with breast cancer in Pakistan. *Cancer Manag Res*.3;11:475-481.doi: 10.2147/CMAR.S184221. eCollection 2019.

Saleem H, Malik SH, Mehdi SR. Oct-Dec 2018. Massive Haemorrhage In Patient After Repair Of Post Esophagectomy Diaphragmatic Hernia And A Loading Dose Of Clopidogrel. *J Ayub Med Coll Abbottabad*;30(4):611-613.

Malik SH, Hafeez H, Malik NH, Rehman Ghafoor AU. Oct-Dec 2018. Coeliac Plexus Neurolysis For Pancreatic Cancer Patients; Retrospective Analysis Of Shaukat Khanum Memorial Cancer Hospital & Research Centre Experience. *J Ayub Med Coll Abbottabad*;30(4):516-519.

Baqari SAS, Razi M, Hayat J, Wali RM. Jan 2019. Classical Hodgkin's Lymphoma with Skeletal Muscle Involvement: A Testing Case. *J Coll Physicians Surg Pak*; 29(1):81-83. doi: 10.29271/jcpsp.2019.01.81.

Adeel M, Rajput MSA, Arain AA, Baloch M, Khan M. Oct 2018. Ameloblastoma: Management and Outcome.

Cureus;10(10):e3437. doi: 10.7759/cureus.3437.

Ashraf MU, Iman K, Khalid MF, Salman HM, Shafi T, Rafi M, Javaid N, Hussain R, Ahmad F, Shahzad-UI-Hussan S, Mirza S, Shafiq M, Afzal S, Hamera S, Anwar S, Qazi R, et al. Dec 2018. Evolution of efficacious pangenotypic hepatitis C virus therapies. *Med Res Rev.* doi: 10.1002/med.21554. Review.

Shabbir Z, Javaid A; Islah Ud Din . Dec 2018. Infantile Hepatic Hemangioma. *J Pak Med Assoc*;68(12):1846-1847.

Hassan U, Rana IA, Mushtaq S, Azam M, Akhter N. Nov 2018. Follicular Dendritic Cell Sarcoma of Gastrointestinal Tract: an Uncommon Lesion, Commonly Missed. *J Gastrointest Cancer*. doi: 10.1007/s12029-018-0178-0

Elahi E, Zia U, Bhutta OA, Andleeb S. Nov 2018. Extrapyrimal symptoms resulting from risperidone use in a four year old child: A case report. *J Pak Med Assoc*;68(11):1719-1720.

Hidiroglu S, Kulbay H, Karavus M, Onsuz F. Nov 2018. Expectations, requirements, and problems of family health care workers providing home services in Turkey. *J Pak Med Assoc*;68(11):1696-1698.

Adeel M, Siddiqi MI. Oct 2018. Metachronous second primary malignancy in head and neck cancer patients: is five years of follow-up sufficient? *J Korean Assoc Oral Maxillofac Surg*;44(5):220-224. doi: 10.5125/jkaoms.2018.44.5.220.

Kalra S, Czupryniak L, and Raza SA et al. Dec 2018. Expert Opinion: Patient Selection for Premixed Insulin Formulations in Diabetes Care. *Diabetes Ther*;9(6):2185-2199. doi: 10.1007/s13300-018-0521-2. Review.

Ahmad S, Anees M, Akbar H, Akhtar N. Nov 2018. Granulomatous Interstitial Nephritis: A Rare Cause of Acute Kidney Injury. *J Coll Physicians Surg Pak*;28(11):885-887. doi: 10.29271/jcpsp.2018.11.885.

Saeed KM, Khattak S, Syed AA, Yusuf MA. Jul-Sep 2018. Oesophageal stents for the treatment of radiation and anastomotic oesophageal strictures. *Acta Gastroenterol Belg*;81(3):361-365.

Anwer AW, Faisal M, Adeel M, Waqas O, Abu Bakar M, Qadeer S, Koukab M, Hussain R, Jamshed A. Aug 2018. Clinicopathological Behavior and Treatment-related Outcome of Rare Salivary Duct Carcinoma: The Shaukat Khanum Memorial Cancer Hospital Experience. *Cureus*;10(8):e3139. doi: 10.7759/cureus.3139.

Riaz S, Bashir H, Khan SJ, Qazi A. Oct 2018. I-131 mIBG Scintigraphy Curie Versus SIOPEN Scoring: Prognostic Value in Stage 4 Neuroblastoma. *Mol Imaging Radionucl Ther*;27(3):121-125. doi: 10.4274/mirt.52533.

Farooq U, Qazi AQ, Malik AA. Jul 2018. Short term surgical outcomes of Wilms tumour from a single institute. *J Pak Med Assoc*;68(7):1129-1131.

Majeed S, Mushtaq S, Azam M, Akhtar N, Hussain M, Loya A. Jul 2018. Diagnostic accuracy of glypican-3 in differentiating hepatocellular carcinoma from metastatic liver tumours. *J Pak Med Assoc*;68(7):1029-1031.

Rashid MU, Khan FA, Muhammad N, Loya A, Hamann U. Oct 2018. Prevalence of PALB2 Germline Mutations in Early-onset and Familial Breast/Ovarian Cancer Patients from Pakistan. *Cancer Res Treat.* doi: 10.4143/crt.2018.356.

Naveed MA, Mangla R, Idrees H, Mehta RI. Sep 2018. Remote Cerebellar Haemorrhage: A Potential Iatrogenic Complication of Spinal Surgery. *Case Rep Neurol Med*;2018:5870584. doi: 10.1155/2018/5870584. eCollection 2018

Gul N, Parveen A, Zaka N, Rafique M. Oct 2018. J Coll Physicians Surg Pak;28(10):748-752. doi: 3014.

Khan SJ, Arshad AA, Fayyaz MB, Ud Din Mirza I. Sep 2018. Posterior Reversible Encephalopathy Syndrome in Pediatric Cancer: Clinical and Radiologic Findings. J Glob Oncol;4(1):1-8. doi: 10.1200/JGO.17.00089.

Hannan A, Khalid MF, Yasmeen S. Jul-Aug 2018. Germ cell tumor and Takotsubo Cardiomyopathy: A treatment dilemma.

Pak J Med Sci;34(4):1030-1033. doi: 10.12669/pjms.344.15293.

Shaefer JR, Khawaja SN, Bavia PF. Oct 2018. Sex, Gender, and Orofacial Pain. Dent Clin North Am;62(4):665-682. doi: 10.1016/j.cden.2018.06.001. Review.

Atiq A, Atiq M, Iqbal K, Sial MA, Altaf S, Shamsi QA, Buzdar SA. Jan-Mar 2018. A comparative study of RapidArc and intensity-modulated radiotherapy plan quality for cervical cancer treatment. Indian J Cancer;55(1):74-79. doi: 10.4103/ijc.IJC_609_17.

Faisal M, Abu Bakar M, Sarwar A, Adeel M, Batool F, Malik KI, Jamshed A, Hussain R. Aug 2018. Depth of invasion (DOI) as a predictor of cervical nodal metastasis and local recurrence in early stage squamous cell carcinoma of oral tongue (ESSCOT). PLoS One;13(8):e0202632. doi: 10.1371/journal.pone.0202632. eCollection 2018.

Badar F. Aug 2018. Comments on Suhail Anwar (J Pak Med Assoc. 68: 692-693, 2018) The role of a cancer registry in a health-care system. J Pak Med Assoc;68(8):1279.

Ishaq A, Khan MJH, Pishori T, Soomro R, Khan S. Jul 2018. Location of appendix in pregnancy: does it change? Clin Exp Gastroenterol;11:281-287. doi: 10.2147/CEG.S154913. eCollection 2018.

Siddique M, Bashir H. Nov 2018. 99mTc Sodium Pertechnetate Uptake in Ectopic Mediastinal Thyroid Tissue on Hybrid Thyroid Scintigraphy. Clin Nucl Med;43(11):820-822. doi: 10.1097/RLU.0000000000002201.

Hameed A, Ali J, Munawar K, Arshad F, Badar F, Siddiqui N. Feb 2018. Characteristics and outcomes of patients with multiple myeloma: Data from a developing country. Med J Islam Repub Iran;32:1. doi: 10.14196/mjiri.32.1. eCollection 2018.

Batool S, Malik AA, Bari H, Islam IU, Hanif F. Jun 2018. Vascular Resection and Reconstruction in Pancreatic Tumours. J Coll Physicians Surg Pak;28(6):485-487. doi: 10.29271/jcpsp.2018.06.485.

Kalra S, and Syed AR at el. Jan-Feb 2018. Consensus Recommendations on Sulfonylurea and Sulfonylurea Combinations in the Management of Type 2 Diabetes Mellitus – International Task Force. Indian J Endocrinol Metab;22(1):132-157. doi: 10.4103/ijem.IJEM_556_17. Review.

Mohy-Ud-Din H, Boutagy NE, Stendahl JC, Zhuang ZW, Sinusas AJ, Liu C. Dec 2018. Quantification of intramyocardial blood volume with 99mTc-RBC SPECT-CT imaging: A preclinical study. J Nucl Cardiol;25(6):2096-2111. doi: 10.1007/s12350-017-0970-4.

Ajmal Ghouri MS, Hassan A. Oct 2018. Sentinel node mapping in vulvar carcinoma. J Pak Med Assoc;68(10):1546.

Asghar N, Hassan A. Sep 2018. A rare presentation of osseous metastasis in Hepatocellular Carcinoma (HCC) on bone scintigraphy. J Pak Med Assoc;68(9):1415.

- Anwar S, Hassan A. Aug 2018. Physiological Uptake of F18-FDG in breast parenchyma. *J Pak Med Assoc.*;68(8):1278.
- Rashid N, Hassan A. Jul 2018. Calcified dural based meningioma, mimicker of metastasis on skeletal scintigraphy. *J Pak Med Assoc.*;68(7):1140.
- Razi M, Bashir H, Hassan A, Niazi IK. Jun 2018. False positive finding of F18-FDG in non-Hodgkins lymphoma; an inflamed appendix. *J Pak Med Assoc.*;68(6):971.
- Majeed N, Bakar MA, Raza A, Parveen A, Sultan F. 2018. Factors and outcome in cancer patients with bacteremia caused by methicillin sensitive and methicillin resistant *Staphylococcus aureus* at a specialized cancer center in Pakistan. *Infectious Diseases Journal of Pakistan.* ;26(3):
- Adeel M, Faisal M, Rashid A, Usman S, Khaleeq U, Abbas T, Rehman A, Malik K, Hussain R, Jamshed A. 1 jun 2018. An Overview of Laryngeal Cancer Treatment at a Tertiary Care Oncological Center in a Developing Country. *Cureus.*;10(6):e2730. doi: 10.7759/cureus.2730.
- Das JK, Hasan R, Zafar A, Ahmed I, Ikram A, Nizamuddin S, Fatima S, Akbar N, Sultan F, Bhutta ZA. 25 Jul 2018. Trends, Associations, and Antimicrobial Resistance of *Salmonella Typhi* and *Paratyphi* in Pakistan. *Am J Trop Med Hyg.* doi: 10.4269/ajtmh.18-0145.
- Siddique M, Nawaz MK, Bashir H. Spring 2018. The Usefulness of SPECT/CT in Sentinel Node Mapping of Early Stage Breast Cancer Patients Showing Negative or Equivocal Findings on Planar Scintigraphy. *Asia Ocean J Nucl Med Biol.*;6(2):80-89. doi: 10.22038/aojnmb.2018.10720.
- Murtaza G, Siddiqui A, Hussain I. 8 Jul 2018. Recent progress in the therapeutic role of serelaxin in vascular dysfunction. *Curr Protein Pept Sci.* doi:10.2174/1389203719666180709103020.
- Tariq U, Parveen A, Akhtar F, Mahmood F, Ali S, Abidi SH. 26 Jul 2018. Emergence of Circulating Recombinant Form 56_cpx in Pakistan. *AIDS Res Hum Retroviruses.* doi: 10.1089/AID.2018.0128.
- Hassan A, Riaz S, Asif A. 7 Jun 2018. Hypermetabolic Hurthle Cell Adenoma on 18F-FDG PET/CT. *Mol Imaging Radionucl Ther.*;27(2):96-98. doi: 10.4274/mirt.49469.
- Riaz S, Bashir H, Hassan A, Khan AH. May 2018. Kohler disease: Imaging King Tut's foot in 21st century. *J Pak Med Assoc.*;68(5):822.
- Tajammul SS, Ali U, Kazi F, Mahmood H. Jun 2018. Secondary Ameloblastic Carcinoma of Mandible with Pulmonary Metastasis. *J Coll Physicians Surg Pak.*;28(6):S117-S119. doi: 10.29271/jcpsp.2018.06.S117.
- Vallabhaneni D, Naveed MA, Mangla R, Zidan A, Mehta RI. 6 May 2018. Perfusion Imaging in Autoimmune Encephalitis. *Case Rep Radiol.*;2018:3538645. doi: 10.1155/2018/3538645. eCollection 2018.
- Khan SJ, Kazmi A. Jun 2018. Radiotherapy Outcome for Pediatric Pelvic Ewing Sarcoma. *J Coll Physicians Surg Pak.*;28(6):445-447. doi: 10.29271/jcpsp.2018.06.445.
- Haeffs TH, D'Amato LN, Khawaja SN, Keith DA, Scrivani SJ. 26 Apr 2018. What Variables Are Associated With the Outcome of Arthroscopic Lysis and Lavage Surgery for Internal Derangement of the Temporomandibular Joint? *J Oral Maxillofac Surg.* pii: S0278-2391(18)30383-5. doi: 10.1016/j.joms.2018.04.018.

- Pal KMI, Ali A, Bari H. May 2018. Role of Percutaneous Cholecystostomy Tube Placement in the Management of Acute Calculus Cholecystitis in High Risk Patients. *J Coll Physicians Surg Pak*;28(5):386-389. doi: 10.29271/jcp-sp.2018.05.386.
- Naeem N, Mushtaq S, Akhter N, Hussain M, Hassan U. May 2018. Effectiveness of Vascular Markers (Immunohistochemical Stains) in Soft Tissue Sarcomas. *J Coll Physicians Surg Pak*;28(5):352-356. doi: 10.29271/jcpsp.2018.05.352.
- Faisal M, Abbas T, Adeel M, Khaleeq U, Anwer AW, Malik K, Hussain R, Jamshed A. 5 Feb 2018. Clinicopathological Behavior and Oncological Outcomes of Malignant Parotid Tumors in a Pakistani Population. *Cureus*;10(2):e2157. doi: 10.7759/cureus.2157.
- Habibullah G, Gul R, Cassum S, Elahi R. Apr-Jun 2018. Experiences of the Breast Cancer Patients Undergoing Radiotherapy at a Public Hospital Peshawar Pakistan. *Asia Pac J Oncol Nurs*;5(2):184-194. doi: 10.4103/apjon.apjon_70_17.
- Asif A, Mushtaq S, Hassan U, Akhtar N, Hussain M, Azam M, Qazi R. 27 Mar 2018. Fluorescence in Situ Hybridization (FISH) for Differential Diagnosis of Soft Tissue Sarcomas. *Asian Pac J Cancer Prev*;19(3):655-660.
- Flaifel A, Tabaja F, Bannoura S, Loya A, Mushtaq S, Khalifeh I. 9 Mar 2018. Patterns of pathologically confirmed metastasis to bone in Near East population. *Cancer Epidemiol*;54:7-11. doi: 10.1016/j.canep.2018.03.002.
- Riaz S, Bashir H, Niazi IK, Butt S, Qamar F. Jun 2018. 99mTc MDP SPECT-CT-Based Modified Mirels Classification for Evaluation of Risk of Fracture in Skeletal Metastasis: A Pilot Study. *Clin Nucl Med*;43(6):e180-e183. doi: 10.1097/R-LU.0000000000002057.
- Hameed A, Ali J, Munawar K, Arshad F, Badar F, Siddiqui N. 2018. Characteristics and outcomes of patients with multiple myeloma: Data from a developing country. *Med J Islam Repub Iran*;32(1):1-5. <https://doi.org/10.14196/mjiri.32.1>
- Akram M, Ullah Zulkafal HM, Altaf S, Iqbal K, Altaf SM, Khan MA, Buzdar SA. Feb 2018. Radiation absorbed dose for cobalt-60 gamma source in phantoms for different materials. *J Pak Med Assoc*;68(2):264-267.
- Rebeck TR and Rashid MU at el. 15 Feb 2018. Mutational Spectrum in a Worldwide Study of 29,700 Families with BRCA1 or BRCA2 Mutations. *Hum Mutat*. doi:10.1002/humu.23406.
- Jahangir S, Loya A, Mushtaq S, Munir J. Jan 2018. Intracortical Lipoma of Tibia in an Adult. *J Coll Physicians Surg Pak*;28(1):85. doi: 10.29271/jcpsp.2018.01.85
- Faisal M, Haider I, Adeel M, Waqas O, Hussain R, Jamshed A. Jan 2018. Small cell neuroendocrine carcinoma of nose and paranasal sinuses: The Shaukat Khanum Memorial Cancer Hospital experience and review of literature. *J Pak Med Assoc*;68(1):133-136.
- Lu L, Ma X, Mohy-Ud-Din H, Ma J, Feng Q, Rahmim A, Chen W. Feb 2018. Enhancement of dynamic myocardial perfusion PET images based on low-rank plus sparse decomposition. *Comput Methods Programs Biomed*;154:57-69. doi: 10.1016/j.cmpb.2017.10.020.
- Scrivani SJ, Khawaja SN, Bavaria PF. Feb 2018. Nonsurgical Management of Pediatric Temporomandibular Joint Dysfunction. *Oral Maxillofac Surg Clin North Am*;30(1):35-45. doi: 10.1016/j.coms.2017.08.001.

- Blood Bank → بلڈ بینک
- Medical Record → میڈیکل ریکارڈ
- Services Building → سروسز بلڈنگ
- Visitors' Cafeteria → طعام گاہ برائے مریضوں و لواحقین
- Pharmacy → دواخانہ

Financial Support Services → خدمات برائے مالی اعوان

Patient Admission/Discharge Counter → دفتر داخلہ و نکلنے والے مریضوں کے لیے



6



A photograph of a modern office hallway. On the left, there are several glass-walled rooms or cubicles. Inside one of them, a computer monitor and a green office chair are visible. The hallway has a light-colored floor with a darker stripe running down the center. The ceiling is white with recessed fluorescent lighting. A large, semi-transparent orange rectangle is overlaid in the center of the image, containing the text "HIGHLIGHTS OF THE YEAR 2018" in white, bold, sans-serif font.

HIGHLIGHTS OF THE YEAR 2018



“The JCI evaluates and tests international healthcare organisations to the same exacting standards applied to those in the US.”

SKMCH&RC, LAHORE: OUR JOURNEY TOWARDS JOINT COMMISSION INTERNATIONAL ACCREDITATION

Shaikat Khanum Memorial Cancer Hospital and Research Centre, Lahore was established with the vision to provide quality cancer care to all its patients, irrespective of their ability to pay. Quality care was enshrined in the mission statement and has been woven into the ethos and culture of the organization, ever since it opened in 1994. In line with this vision, the Hospital sought, from an early stage to gain external validation of the quality of its systems. Initially, the institution embarked on the ISO certification process, receiving Quality Management Systems Certificates for many of its departments starting in 2001. The Hospital sought continuously to improve the standard of patient care delivery and decided in 2004 to work towards attaining what is generally considered to be the gold standard of patient safety and quality care in the world, namely accreditation from the Joint Commission International or JCI.

The JCI was established in 1997 as the international arm of the JCAHO, the Joint Commission for Accreditation of Healthcare Organisations, which accredits all US hospitals. The JCI evaluates and tests international healthcare organisations to the same exacting standards applied to those in the US. Through international accreditation, consultation, publications and education programmes, the JCI extends the Joint Commission’s mission worldwide by helping to improve the quality of patient care.

“By 2017, the JCI had issued a new, updated set of standards, meaning that we would be the first institution in Pakistan to be tested against these most exacting of measures.”

“Four multidisciplinary tracer teams were formed in June 2017 to conduct mock tracers in all areas of the Hospital to prepare the staff for the actual survey.”



“Hundreds of staff members worked extra evenings and weekends for close to three months, in order to ensure readiness for JCI survey.”

Starting in 2004, we commenced our long journey towards JCI accreditation by hiring personnel with knowledge of this process, by restructuring of policies and procedures, intensive staff training and a continuous, system-wide, multi-level process of continuous quality improvement. Some staff members were chosen to undergo focused training in JCI standards and methodologies, in 2007, and a team of professionals from the Aga Khan University Hospital in Karachi were invited to carry out mock audits to test our readiness in 2008 and again in 2011. These audits provided considerable confidence and reassurance as to our state of

preparedness and we sent in our first application in October 2011. However an actual survey could not be performed due to travel advisories by the US government which prevented surveyors from the US from coming to Pakistan for several years. Eventually, this roadblock was overcome, however, and we therefore felt ourselves able to re-apply for a survey in 2017, redoubling our preparatory activities in parallel. By this time, the JCI had issued a new, updated set of standards, meaning that we would be the first institution in Pakistan to be tested against these most exacting of measures.

Four multidisciplinary tracer teams (each including a physician, a nurse, a pharmacist, and a facility assessor) were formed in June 2017 to conduct mock tracers in all areas of the Hospital to prepare the staff for the actual survey. Help and advice was sought from the recently accredited Shifa International Hospital in Islamabad, and a team from SKMCH&RC visited this institution in the autumn of 2017 to learn from their experiences during their journey to JCI accreditation. This visit proved to be very useful and we felt sufficiently confident thereafter, to submit our application for a survey to the JCI in September 2017. A survey date in late April 2018 was agreed upon by the JCI. Momentum built rapidly, thereafter, with the entire staff putting their shoulder to the wheel, determined as they were to meet the challenge ahead. We were fortunate, in February 2018, to have a team of experienced staff from the Shifa International Hospital, Islamabad conduct a final mock audit over two days, which again helped us highlight lacunae in our preparations. Increasing numbers of staff were required to become directly involved in teaching, training and testing, over these last few months, with many hundreds of staff members working extra evenings and weekends for close to three months, in order to ensure readiness.

In April 2018, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore underwent a rigorous on-site survey during which a team of expert surveyors from the Joint Commission International evaluated compli-

ance with hospital standards related to a variety of areas, including the International Patient Safety Goals, patient assessment and care, anaesthesia and surgical care, medication management and usage, patient and family education, quality improvement, infection prevention and control, governance and leadership, facility management, staff qualifications and evaluation and information management. At the end of a grueling, week-long process, all the hard work put in over many years came to fruition, when the final result was announced by the JCI in Chicago, with

Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore successfully earning the Joint Commission International's Gold Seal of Approval® for Hospital Accreditation by demonstrating continuous compliance with its internationally-recognised standards.

The Gold Seal of Approval® is a symbol of quality that reflects an organization's commitment to providing safe and effective patient care.

The hospital leadership would like to formally recognize and appreciate the tireless efforts of all our staff in making this possible, as well as to acknowledge and thank our friends and colleagues at the two existing JCI accredited organisations in Pakistan, namely the Aga Khan University Hospital in Karachi and Shifa International Hospital, Islamabad, all of whom were always available to us for help, advice and support.

“The hospital leadership would like to formally appreciate the tireless efforts of all our staff as well as our friends and colleagues at the two existing JCI accredited organisations in Pakistan”





PAIN MANAGEMENT SERVICE COMMENCES AT SKMCH&RC, PESHAWAR

Cancer patients may experience pain at various points during the course of the disease. It can be short-lived or long-lasting, mild or severe, and can affect one or more parts of the body. Regardless of the type, pain can greatly disrupt a patient's day-to-day activities including eating and sleeping and it can become a cause of constant discomfort and irritability. Fortunately, pain associated with cancer is treatable and adequate pain management can be very important, allowing cancer patients to enjoy precious moments with their families.

As each patient's pain is unique, SKMCH&RC tailors the treatment plan for pain management so as to address each patient's specific needs. We are pleased to be able to say that Shaukat Khanum Memorial Cancer Hospital and Research Centre (SKMCH&RC) in Peshawar is now offering an interventional head and neck pain management service for its patients. Previously, patients had to travel to SKMCH&RC in Lahore to avail this service and to seek relief from pain. The new service has brought pain relief closer to the homes of patients. This service will provide various procedures in an out-patient setting. Initially this service is available once a month for Hospital patients however, in the future, the availability of the service is planned to be extended to twice a month.

EMERGENCY ASSESSMENT ROOM EXPANSION AT SKMCH&RC, LAHORE

On average, SKMCH&RC, Lahore registers nearly 10,000 new patients each year. In addition to newly registered patients, we continue to care for patients registered in past years who have successfully completed cancer treatment and are now on follow-up. This means that, at any given time, we have over 20,000 active patients in the system, which requires continuous investment in the expansion of our facilities. The newly constructed Endoscopy Unit vacated space which allowed for the expansion of our emergency services, allowing us to create two separate Emergency Assessment Rooms for children and for adults, more than doubling our capacity in the process.



Infinia



DONATION PROGRAMMES



ZAKAT

“AND WHOEVER
SAVED A LIFE, IT
WOULD BE AS IF
HE SAVED ALL
MANKIND”



Your Zakat allows SKMCH&RC to provide financially supported treatment to nearly 75% of its cancer patients. Zakat is exclusively utilized for providing direct patient care to the poor patients. Donate generously to keep the hope alive for thousands of poor cancer patients.



You can give any amount on account of Zakat.

Your Zakat will be utilized in providing free treatment facilities to eligible cancer patients within the same year.



MONTHLY DONATION

BECOME
A PARTNER IN
HOPE

You can pledge a monthly contribution for the project of your choice and make an ongoing commitment to our mission of fighting cancer. By choosing this convenient mode, your contribution will be automatically deducted, allowing you to make a difference in the lives of cancer patients every month.



Construction of Pakistan's third SKMCH&RC, Karachi

Construction of New Clinical Tower at SKMCH&RC, Lahore

Completion of Phase III of SKMCH&RC, Peshawar

Setup auto-deduction from your bank account or credit card by visiting our website.

SPONSORSHIP OF EQUIPMENT

YOUR DONATION
EQUIPS US TO
FIGHT CANCER



In line with its mission, SKMCH&RC strives to provide the highest quality of care by investing in the latest technology and treatment facilities for its patients. You can sponsor equipment and help the Hospital acquire new medical equipment to keep abreast with some of the best cancer centres of the world.

Sponsorship of Equipment from Rs. 10,000 to Rs. 100 million.

View the full range of Equipment Sponsorship Menu for our projects by visiting our website.

SPONSORSHIP OF PROJECTS

CEMENT THE
BRICKS IN THE
MEMORY OF
LOVED ONES



You can create a lasting legacy of hope by sponsoring a room/area in your name or in your loved one's name. For this life-long dedication, your name or your loved one's name will be inscribed on a plaque outside the dedicated room/area.



Life-long dedication of area/rooms starting from Rs. 1 million.

View the full range of rooms/areas available for Sponsorship/Dedication in Lahore, Karachi and Peshawar Projects by visiting our website.

Note: All pledges are to be paid within one year from the date of pledge.

FOUNDING DONOR

MAKE YOUR
NAME LIVE ON
FOREVER



You can become a Founding Donor, which is a lifetime dedication, at a one-time sponsorship cost of Rs. 500,000. If you become a Founding Donor, your name or the name of a loved one will be etched on the Founding Donor Monument, which will be built within the premises of the project of your choice.



Founding Donor of Pakistan's third SKMCH&RC (Karachi) Rs. 500,000

Founding Donor of New Clinical Tower (Lahore) Rs. 500,000

Founding Donor of Phase III of SKMCH&RC (Peshawar) Rs. 500,000

Note: All pledges are to be paid within one year from the date of pledge.



SPONSOR A CANCER PATIENT

SAVE A DREAM

The Sponsor a Cancer Patient Programme allows you to assume direct responsibility for the treatment of one or more named cancer patients. As a prospective sponsor, you will be provided with profiles of patients along with the expected treatment costs. You can sponsor a cancer patient and join us as we accompany our patients in their journey of hope.



Lymphoma	Rs. 875,000
Ovarian Cancer	Rs. 900,000
Lung Cancer	Rs. 1,000,000
Breast Cancer	Rs. 1,000,000
Blood Cancer	Rs. 2,000,000

DONATE A MEAL

EACH MEAL CAN HELP HEAL



You can donate a meal for our cancer patients and help us fulfill the special dietary needs of cancer patients at the Hospital, giving them the strength to fight cancer. Each meal is prepared with specific attention to hygiene and particular nutritional needs of the patients. Donate a meal today because Each Meal Can Help Heal.



Sponsor the meal of financially supported patients admitted in the Paediatric Unit for one month

Rs. 500,000

Sponsor the meals of 100 patients for one week

Rs. 350,000

Sponsor the meals of all financially supported patients admitted at the Hospital for one day

Rs. 100,000

HOW TO DONATE

<https://shaukatkhanum.org.pk/donors/>





VARIAN
medical systems

VARIAN



FINANCIALS

unique

FINANCIAL REPORTS

5 YEARS PERFORMANCE AT A GLANCE

5 years performance at a glance	(Rs. in Millions)				
For the years ending December 31	2018	2017	2016	2015	2014
Clinical Income	4,467	3,933	3,739	3,384	2,924
Other Income	6,553	5,013	4,716	5,809	3,448
Total Income	11,020	8,946	8,456	9,193	6,372
Expenses					
Clinical expenses	6,987	5,924	5,346	4,751	4,099
General and administrative expenses	2,220	1,945	1,629	1,184	1,135
Marketing expenses	820	568	466	461	290
Finance cost	19	24	25	17	33
	10,046	8,461	7,466	6,414	5,557
	-				
Surplus before taxation	975	485	989	2,779	815
Provision for taxation	-	-	-	-	-
Surplus of income over expenditure	975	485	989	2,779	815
Surplus ratio	9%	5%	12%	30%	13%

Figures for 2016, 2017 & 2018 include performance of Peshawar Hospital which was inaugurated on December 29, 2015.

5 YEAR POSITION AT A GLANCE

5 years performance at a glance		(Rs. in Millions)				
For the years ending December 31	2018	2017	2016	2015	2014	
Clinical Income	4,467	3,933	3,739	3,384	2,924	
Other Income	6,553	5,013	4,716	5,809	3,448	
Total Income	11,020	8,946	8,456	9,193	6,372	
Expenses						
Clinical expenses	6,987	5,924	5,346	4,751	4,099	
General and administrative expenses	2,220	1,945	1,629	1,184	1,135	
Marketing expenses	820	568	466	461	290	
Finance cost	19	24	25	17	33	
	10,046	8,461	7,466	6,414	5,557	
	-					
Surplus before taxation	975	485	989	2,779	815	
Provision for taxation	-	-	-	-	-	
Surplus of income over expenditure	975	485	989	2,779	815	
Surplus ratio	9%	5%	12%	30%	13%	

Figures for 2016, 2017 & 2018 include performance of Peshawar Hospital which was inaugurated on December 29, 2015.

AUDITOR'S REPORT

SHAUKAT KHANAM MEMORIAL TRUST ('SKMT')

**FINANCIAL STATEMENTS
FOR THE YEAR ENDED
DECEMBER 31, 2018**

In case of any discrepancy on the trust's website, the auditors shall only be responsible in respect of the information contained in the hard copies of the audited financial statement available at the trust's registered office.



INDEPENDENT AUDITORS' REPORT TO THE BOARD OF GOVERNORS OF SHAUKAT KHANUM MEMORIAL TRUST

Opinion

We have audited the financial statements of Shaukat Khanum Memorial Trust (the 'Trust'), which comprise the statement of financial position as at December 31, 2018, and the income and expenditure account, the statement of comprehensive income, the statement of changes in fund balances and the cash flow statement for the year then ended, and notes to the financial statements, including a summary of significant accounting policies.

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the Trust as at December 31, 2018, and of its financial performance and its cash flows for the year then ended in accordance with the International Financial Reporting Standards (IFRS) issued by the International Accounting Standards Board (IASB) as notified by the Securities and Exchange Commission of Pakistan (SECP).

Basis for Opinion

We conducted our audit in accordance with the International Standards on Auditing (ISAs) as applicable in Pakistan. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Trust in accordance with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants as adopted by the Institute of Chartered Accountants of Pakistan (the Code), and we have fulfilled our other ethical responsibilities in accordance with the Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Responsibilities of Management and Those Charged with Governance for the Financial Statements

The Board of Governors are responsible for the preparation and fair presentation of the financial statements in accordance with the IFRS issued by IASB as notified by the SECP, and for such internal control as the Board of Governors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Board of Governors are responsible for assessing the Trust's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Trust or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Trust's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs as applicable in Pakistan will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A. F. FERGUSON & CO., Chartered Accountants, a member firm of the PwC network
23-C, Aziz Avenue, Canal Bank, Gulberg-V, P.O.Box 39, Lahore-54660, Pakistan
Tel: +92 (42) 3571 5868-71 / 3577 5747-50 Fax: +92 (42) 3577 5754 www.pwc.com/pk

■ KARACHI ■ LAHORE ■ ISLAMABAD



As part of an audit in accordance with ISAs as applicable in Pakistan, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Trust's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Trust's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Trust to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.


A. F. Ferguson & Co.
Chartered Accountants

Lahore

Date : May 30, 2019

Name of the engagement partner: Muhammad Masood

SHAUKAT KHANUM MEMORIAL TRUST

STATEMENT OF FINANCIAL POSITION AS AT DECEMBER 31, 2018

	Note	General fund Rupees	Endowment fund Rupees	2018 Rupees	2017 Rupees
FUND BALANCE		<u>10,822,815,561</u>	<u>3,038,343,199</u>	<u>13,861,158,760</u>	<u>12,888,818,533</u>
REPRESENTED BY					
NON-CURRENT ASSETS					
Operating fixed assets - owned	6	9,261,893,042	-	9,261,893,042	7,771,715,254
Intangible assets	7	34,373,494	-	34,373,494	29,493,338
Assets subject to finance lease	8	204,782,374	-	204,782,374	240,017,824
Capital work-in-progress	9	161,297,965	-	161,297,965	176,168,368
Long term loans and deposits	10	36,664,933	-	36,664,933	34,969,918
Long term investments	11	1,481,555	36,889,700	38,371,255	40,779,367
		9,700,493,363	36,889,700	9,737,383,063	8,293,144,069
CURRENT ASSETS					
Stores and spares		14,646,974	-	14,646,974	14,757,054
Stocks	12	871,318,272	-	871,318,272	751,816,806
Donations in kind	13	453,676,489	-	453,676,489	397,568,000
Trade receivables	14	180,387,449	-	180,387,449	158,133,877
Loans, advances, deposits, prepayments and other receivables	15	148,292,574	66,706,100	214,998,674	255,346,128
Short term investments	16	349,250,355	2,367,614,670	2,716,865,025	3,404,616,433
Cash and bank balances	17	1,271,272,309	567,132,729	1,838,405,038	1,124,652,446
		3,288,844,422	3,001,453,499	6,290,297,921	6,106,890,744
LESS: CURRENT LIABILITIES					
Current portion of non-current liabilities	18	88,301,221	-	88,301,221	112,308,472
Trade and other payables	19	1,045,829,625	-	1,045,829,625	992,153,014
		1,134,130,846	-	1,134,130,846	1,104,461,486
LESS: NON-CURRENT LIABILITIES					
Long term loan - secured	20	72,158,035	-	72,158,035	67,334,236
Liabilities against assets subject to finance lease	21	616,792	-	616,792	71,946,450
Deferred liability	22	121,444,351	-	121,444,351	105,071,908
Deferred contributions	23	682,020,000	-	682,020,000	-
Deferred government grants	24	156,152,200	-	156,152,200	162,402,200
		1,032,391,378	-	1,032,391,378	406,754,794
CONTINGENCIES AND COMMITMENTS 25					
NET ASSETS		<u>10,822,815,561</u>	<u>3,038,343,199</u>	<u>13,861,158,760</u>	<u>12,888,818,533</u>

The annexed notes 1 to 38 form an integral part of these financial statements.

MU


Member


Member

SHAUKAT KHANUM MEMORIAL TRUST

INCOME AND EXPENDITURE ACCOUNT FOR THE YEAR ENDED DECEMBER 31, 2018

	Note	General fund Rupees	Endowment fund Rupees	2018 Rupees	2017 Rupees
Income					
Clinical income	26	4,467,105,295	-	4,467,105,295	3,933,497,186
Other income	27	6,161,899,822	391,371,993	6,553,271,815	5,012,950,263
Total income for the year		10,629,005,117	391,371,993	11,020,377,110	8,946,447,449
Expenditure					
Clinical expenses	28	6,986,684,433	-	6,986,684,433	5,923,605,007
General and administrative expenses	29	2,215,287,522	-	2,215,287,522	1,916,285,177
Marketing expenses	30	819,906,705	-	819,906,705	567,728,255
Finance cost	31	18,937,185	-	18,937,185	24,095,007
Other expense	32	4,725,000	-	4,725,000	29,285,000
		10,045,540,845	-	10,045,540,845	8,460,998,446
Surplus of income over expenditure before taxation		583,464,272	391,371,993	974,836,265	485,449,003
Taxation	33	-	-	-	-
Surplus of income over expenditure after taxation		583,464,272	391,371,993	974,836,265	485,449,003

The annexed notes 1 to 38 form an integral part of these financial statements.

AK

[Signature]

Member

[Signature]
Member

SHAUKAT KHANUM MEMORIAL TRUST

STATEMENT OF COMPREHENSIVE INCOME FOR THE YEAR ENDED DECEMBER 31, 2018

	General fund Rupees	Endowment fund Rupees	2018 Rupees	2017 Rupees
Surplus of income over expenditure after taxation	583,464,272	391,371,993	974,836,265	485,449,003
Other comprehensive loss:				
Items that may be recalssified subsequently to income and expenditure account :				
Unrealized loss on remeasurement of available-for-sale investments	(255,738)	(2,240,300)	(2,496,038)	(14,705,798)
Items that may not be recalssified subsequently to income and expenditure account	-	-	-	-
Total comprehensive income for the year	<u>583,208,534</u>	<u>389,131,693</u>	<u>972,340,227</u>	<u>470,743,205</u>

The annexed notes 1 to 38 form an integral part of these financial statements.



Member



Member

SHAUKAT KHANUM MEMORIAL TRUST

STATEMENT OF CASH FLOWS FOR THE YEAR ENDED DECEMBER 31, 2018

Note	2018 Rupees	2017 Rupees
Cash flows from operating activities		
Surplus of income over expenditure before taxation	974,836,265	485,449,003
Adjustments for non-cash charges and other items:		
Depreciation on operating fixed assets - owned	870,811,962	717,645,003
Depreciation on assets subject to finance lease	35,235,450	35,235,450
Amortization of intangible assets	18,775,034	7,119,084
Amortization of deferred grants	(6,250,000)	(6,250,000)
Amortization of deferred contributions	(25,260,000)	-
Gain on disposal of operating fixed assets - owned	(1,116,909)	(8,001,614)
Finance cost	11,236,538	16,924,979
Exchange gain - net	(416,504,416)	(134,101,881)
Income from deposits and investments	(222,993,264)	(187,572,345)
Provision for accumulating compensated absences	32,662,165	52,110,541
Reversal of provision against recoverability of investments	(11,300,000)	(2,200,000)
Receivables written off	106,269	782,241
Liabilities no longer payable written back	(6,931,827)	(19,800,380)
Donations in kind - net	(56,108,489)	(4,295,226)
	<u>222,362,513</u>	<u>467,595,852</u>
Surplus before working capital changes	1,197,198,778	953,044,855
Effect on cash flow due to working capital changes :		
Decrease/ (increase) in stores and spares	110,080	(456,086)
Increase in stocks	(119,501,466)	(169,057,640)
(Increase)/ decrease in trade receivables	(22,359,841)	1,744,215
Decrease/ (increase) in loans, advances, deposits, prepayments and other receivables	39,882,426	(29,923,506)
Increase in trade and other payables	60,581,962	88,803,509
	<u>(41,286,839)</u>	<u>(108,889,508)</u>
Cash generated from operations	1,155,911,939	844,155,347
Finance cost paid	(11,210,062)	(16,834,378)
Payment of accumulating compensated absences	(16,289,722)	(20,618,187)
Income tax paid	(2,231,726)	(2,309,634)
Net increase in long term loans and deposits	(1,695,015)	(9,974,318)
	<u>1,124,485,414</u>	<u>794,418,830</u>
Net cash inflow from operating activities		
Cash flows from investing activities		
Purchase of operating fixed assets - owned	(1,641,875,583)	(784,853,739)
Purchase of intangible assets	(23,655,190)	(36,612,422)
Proceeds from disposal of operating fixed assets - owned	4,153,145	10,260,033
Proceeds from disposal/maturity of short term investments	4,077,575,486	2,535,822,539
Short term investments made	(2,996,313,693)	(3,950,262,583)
Interest received	202,441,944	138,867,634
	<u>(377,673,891)</u>	<u>(2,086,778,538)</u>
Net cash outflow from investing activities		
Cash flows from financing activities		
Repayment of long term loan - secured	(8,252,721)	(6,614,592)
Repayment of liabilities against assets subject to finance lease	(96,875,100)	(88,786,954)
	<u>(105,127,821)</u>	<u>(95,401,546)</u>
Net cash outflow from financing activities		
Net increase/(decrease) in cash and cash equivalents	641,683,702	(1,387,761,254)
Cash and cash equivalents at the beginning of the year	1,124,652,446	2,476,614,950
Effects of exchange rate on cash and cash equivalents	72,068,890	35,798,750
Cash and cash equivalents at the end of the year	1,838,405,038	1,124,652,446

17

The annexed notes 1 to 38 form an integral part of these financial statements.


Member


Member

SHAUKAT KHANUM MEMORIAL TRUST

STATEMENT OF CHANGES IN FUND BALANCES FOR THE YEAR ENDED DECEMBER 31, 2018

	General Fund			Endowment Fund			Grand total	
	Revaluation surplus on hand - note 5	Unrealized gain/(loss) on Investments	Accumulated surplus of income over expenditure	Total general fund	Unrealized gain/(loss) on Investments	Accumulated surplus of income over expenditure		Total endowment fund
Balance as on January 1, 2017	1,929,931,250	1,760,196	8,314,255,799	10,245,947,245	44,329,041	2,127,799,042	2,172,128,083	12,418,075,328
Surplus of income over expenditure after taxation	-	-	329,399,179	329,399,179	-	156,049,824	156,049,824	485,449,003
Other comprehensive loss for the year	-	(739,397)	-	(739,397)	(13,966,401)	-	(13,966,401)	(14,705,798)
Total comprehensive (loss)/income for the year	-	(739,397)	329,399,179	328,659,782	(13,966,401)	156,049,824	142,083,423	470,743,205
Transfer (from) general fund to endowment fund	-	-	(173,000,000)	(173,000,000)	-	173,000,000	173,000,000	-
Balance as at December 31, 2017	1,929,931,250	1,020,799	8,470,654,978	10,401,607,027	30,362,640	2,456,848,866	2,487,211,506	12,888,818,533
Surplus of income over expenditure after taxation	-	-	583,464,272	583,464,272	-	391,371,993	391,371,993	974,836,265
Other comprehensive loss for the year	-	(255,738)	-	(255,738)	(2,240,300)	-	(2,240,300)	(2,496,038)
Total comprehensive (loss)/income for the year	-	(255,738)	583,464,272	583,208,534	(2,240,300)	391,371,993	389,131,693	972,340,227
Transfer (from) general fund to endowment fund	-	-	(162,000,000)	(162,000,000)	-	162,000,000	162,000,000	-
Balance as at December 31, 2018	1,929,931,250	765,061	8,892,119,250	10,822,815,561	28,122,340	3,010,220,859	3,038,343,199	13,861,158,760

The annexed notes 1 to 38 form an integral part of these financial statements.

M



Member



Member

SHAUKAT KHANUM MEMORIAL TRUST

NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS FOR THE YEAR ENDED DECEMBER 31, 2018

1. Legal status and nature of business

Shaukat Khanum Memorial Trust (hereinafter referred to as 'SKMT' or the 'Trust') was registered in Pakistan on February 27, 1990 under the Societies Registration Act, XXI of 1860. The Board of Governors of the Trust serve in an honorary capacity. The primary purpose of the Trust is to raise funds in Pakistan and abroad for establishing and maintaining general hospitals with emphasis on cancer specialist centers in Pakistan. Registered office and principal office is situated at 7-A Block R-3, M.A. Johar Town, Lahore. Funds raised in the United Kingdom, United States of America, Canada, Australia and Norway are incorporated in the accounts of charitable trusts that are separate legal entities registered in the respective countries. The Trust also has a branch office in Dubai which is registered with International Humanitarian City, Free Zone Authority, Dubai, for creating awareness about the Trust, its hospitals and for fundraising.

Currently, the Trust is managing Shaukat Khanum Memorial Cancer Hospital and Research Centre in Lahore and in Peshawar. Moreover, a diagnostic center in Lahore and Rahim Yar Khan and a chemotherapy facility in Karachi is being managed by the Trust.

2. Basis of preparation

2.1 Statement of compliance

These financial statements have been prepared in accordance with the requirements of International Financial Reporting Standards (IFRS) issued by the International Accounting Standards Board (IASB) as notified by the Securities and Exchange Commission of Pakistan (SECP).

2.2 Initial application of standards, amendments or an interpretation to existing standards

The following amendments to existing standards have been published that are applicable to the Trust's financial statements covering annual periods, beginning on or after the following dates:

2.2.1 Standards, amendments and interpretations to accounting standards that are effective in current year

Certain standards, amendments and interpretations to IFRS are effective for accounting periods beginning on January 1, 2018 but are considered not to be relevant or to have any significant effect on the Trust's operations (although they may affect the accounting for future transactions and events) and are, therefore, not detailed in these financial statements, except for the following:

- IFRIC 22, 'Foreign currency transactions and advance consideration' (effective for periods beginning on or after January 1, 2018). This IFRIC addresses foreign currency transactions or parts of transactions where there is consideration that is denominated or priced in a foreign currency. The interpretation provides guidance for when a single payment/receipt is made as well as for situations where multiple payments/receipts are made. The guidance aims to reduce diversity in practice. The Trust's accounting treatment is already in line with this interpretation.

2.2.2 Standards, amendments and interpretations to existing standards that are not yet effective and have not been early adopted by the Trust

There are certain standards, amendments to the IFRS and interpretations that are mandatory for accounting periods beginning on or after January 1, 2019 but are considered not to be relevant or to have any significant effect on the Trust's operations and are, therefore, not detailed in these financial statements, except for the following:

- IFRS 9, 'Financial instruments': (effective for periods beginning on or after January 1, 2018). This standard has been notified by the SECP to be effective for reporting period/year ending on or after June 30, 2019. This standard replaces the guidance in IAS 39, 'Financial instruments: Recognition and measurement'. It includes requirements on the classification and measurement of financial assets and liabilities; it also includes an expected credit losses model that replaces the current incurred loss impairment model. The Trust is yet to assess the full impact of this standard.

- IFRS 15, 'Revenue from contracts with customers': (effective for periods beginning on or after January 1, 2018). This standard has been notified by the SECP to be effective for annual periods beginning on or after July 1, 2018. This standard deals with revenue recognition and establishes principles for reporting useful information to users of the financial statements about the nature, amount, timing and uncertainty of revenue and cash flows arising from an entity's contracts with customers. Revenue is recognized when a customer obtains control of a good or service and thus has the ability to direct the use and obtain the benefits from the good or service. The standard replaces IAS 18, 'Revenue', and IAS 11, 'Construction contracts', and related interpretations. The Trust is yet to assess the full impact of this standard.

- IFRS 16, 'Leases': (effective for periods beginning on or after January 1, 2019). This standard has been notified by the SECP to be effective for annual periods beginning on or after January 1, 2019. This standard replaces the current guidance in IAS 17, 'Leases' and is a far reaching change in accounting by lessees in particular. Under IAS 17, lessees were required to make a distinction between a finance lease (on statement of financial position) and an operating lease (off statement of financial position). IFRS 16 now requires lessees to recognize a lease liability reflecting future lease payments and a 'right-of-use asset' for virtually all lease contracts. The IASB has included an optional exemption for certain short-term leases and leases of low-value assets; however, this exemption can only be applied by lessees. For lessors, the accounting stays almost the same. However, as the IASB has updated the guidance on the definition of a lease (as well as the guidance on the combination and separation of contracts), lessors will also be affected by the new standard. At the very least, the new accounting model for lessees is expected to impact negotiations between lessors and lessees. The Trust is yet to assess the full impact of the standard.

3. Basis of measurement

3.1 These financial statements have been prepared under the historical cost convention except for the recognition of certain operating fixed assets, donations in kind and financial instruments at fair value.

3.2 Critical accounting estimates and judgements

The Trust's significant accounting policies are stated in note 4. Not all of these significant policies require the management to make difficult, subjective or complex judgements or estimates. The following is intended to provide an understanding of the policies, the management considers critical because of their complexity, judgment of estimation involved in their application and their impact on these financial statements. Estimates and judgments are continually evaluated and are based on historical experience, including expectations of future events that are believed to be reasonable under the circumstances. These judgments involve assumptions or estimates in respect of future events and the actual results may differ from these estimates. The areas involving a higher degree of judgements or complexity or areas where assumptions and estimates are significant to the financial statements are as follows :

a) Useful lives and residual values of operating fixed assets - note 4.4

b) Fair valuation of donations in kind - note 4.14

3.3 For the purpose of translation, rates of Rs 138.60 (2017: Rs 110.30) per US Dollar, Rs 175.88 (2017: Rs 148.45) per GBP, Rs 158.52 (2017: Rs 131.73) per Euro and Rs 37.73 (2017: Rs 30.03) per AED have been used.

4. Significant accounting policies

The significant accounting policies adopted in the preparation of these financial statements are set out below. These policies have been consistently applied to all years presented, unless otherwise stated.

4.1 General Fund

This is a general purpose fund. All donations and zakat, other than those which are required to be retained for the benefit of the Trust as a capital fund, are recognized in this fund.

4.2 Endowment Fund

This is a form of restricted fund which is held on trust to be retained for the benefit of the Trust as a capital fund. The income generated from this capital fund is also credited to this fund. The main objective of the fund is to generate income for the operating expenses of Shaukat Khanum Memorial Cancer Hospital & Research Centre.

4.3 Taxation

The Trust is exempt from income tax under clause 66 part I of the Second Schedule of the Income Tax Ordinance, 2001. Consequently no provision for taxation was made in these financial statements.

4.4 Property, plant and equipment

4.4.1 Operating fixed assets

4.4.1.1 Owned assets

Owned assets, except for freehold land, are stated at cost less accumulated depreciation and any identified impairment loss. Freehold land is stated at revalued amount less any identified impairment loss. Revaluation is carried out with sufficient regularity to ensure that the carrying amount of asset does not differ materially from its fair value. Revalued amount has been determined by an independent professional valuer. Increases in the carrying amount arising on revaluation of land are credited to 'revaluation surplus on land' in the fund. Decreases that offset previous increases of the same assets are charged against this surplus, all other decreases are charged to income and expenditure account.

Depreciation on all items of owned assets, except for freehold land, is charged to income and expenditure account using the straight line method so as to write off the depreciable amount of the assets over their estimated useful lives, at the annual rates given in note 6.

The assets' residual values and useful lives are continually reviewed by the Trust and adjusted if impact on depreciation is significant. The Trust's estimate of the residual values and useful lives of its owned assets as at December 31, 2018 has not required any adjustment as its impact is considered insignificant.

An asset's carrying amount is written down immediately to its recoverable amount if the asset's carrying amount is greater than its estimated recoverable amount (note 4.6).

Subsequent costs are included in the asset's carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Trust and the cost of the item can be measured reliably. All other repair and maintenance costs are charged to income and expenditure account during the period in which they are incurred.

The gain or loss on disposal or retirement of an asset represented by the difference between the sale proceeds and the carrying amount of the asset is recognized as an income or expense.

4.4.1.2 Assets subject to finance lease

Assets acquired under a finance lease are depreciated over the estimated useful life of the asset on a straight-line method over its estimated useful life at the annual rates given in note 8. Depreciation of leased assets is charged to income and expenditure account.

Residual values and the useful lives of leased assets are reviewed at each financial year end and adjusted if impact on depreciation is significant. The Trust's estimate of the residual value of its leased assets as at December 31, 2018 has not required any adjustment as its impact is considered insignificant.



4.4.2 Capital work-in-progress

Capital work-in-progress is stated at cost less any identified impairment loss. All expenditure connected with specific assets incurred during installation and construction period are carried under capital work-in-progress. These are transferred to operating fixed assets as and when these are available for use.

4.5 Intangible assets

Computer softwares

Expenditure incurred to acquire computer software is capitalized as intangible asset and stated at cost less accumulated amortization and any identified impairment loss. Computer softwares are amortized using the straight line method over a period of three years.

Amortization on additions to computer softwares are charged from the month in which the asset is acquired or capitalized for use while no amortization is charged for the month in which the asset is disposed of.

An asset's carrying amount is written down immediately to its recoverable amount if the asset's carrying amount is greater than its estimated recoverable amount (note 4.6).

4.6 Impairment of non-financial assets

Goodwill, intangible assets and operating fixed assets that have an indefinite useful life are not subject to amortization/depreciation and are tested annually for impairment, or more frequently if events or changes in circumstances indicate that they might be impaired. Other assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognized for the amount by which the asset's carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset's fair value less costs of disposal and value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash inflows which are largely independent of the cash inflows from other assets or groups of assets (cash-generating units). Non-financial assets other than goodwill that suffered an impairment are reviewed for possible reversal of the impairment at the end of each reporting period.

4.7 Leases

The Trust is the lessee:

4.7.1 Finance leases

Leases where the Trust has substantially all the risks and rewards of ownership are classified as finance leases. At inception, finance leases are capitalized at the lower of present value of minimum lease payments under the lease agreements and the fair value of the assets.

The related rental obligations, net of finance cost, are included in liabilities against assets subject to finance lease as referred to in note 21. The liabilities are classified as current and non-current depending upon the timing of the payment.

Each lease payment is allocated between the liability and finance cost so as to achieve a constant rate on the balance outstanding. The interest element of the rental is charged to income and expenditure account over the lease term.

4.7.2 Operating leases

Leases where a significant portion of the risks and rewards of ownership are retained by the lessor are classified as operating leases. Payments made under operating leases (net of any incentives received from the lessor) are charged to income on a straight-line basis over the lease term.

4.8 Investments

Investments intended to be held for less than twelve months from the statement of financial position date or to be sold to raise operating capital are included in current assets, all other investments are classified as non-current assets. Management determines the appropriate classification of its investments at the time of the purchase and re-evaluates such designation on a regular basis.

Investments made by the Trust are classified for the purpose of measurement into the following categories as explained in note 4.9.

4.9 Financial assets

4.9.1 Classification

The Trust classifies its financial assets in the following categories: at fair value through profit or loss, loans and receivables, available-for-sale and held to maturity. The classification depends on the purpose for which the financial assets were acquired. Management determines the classification of its financial assets at the time of initial recognition.

a) Financial assets at fair value through profit or loss

Financial assets at fair value through profit or loss are financial assets held for trading and financial assets designated upon initial recognition as at fair value through profit or loss. A financial asset is classified as held for trading if acquired principally for the purpose of selling in the short term. Assets in this category are classified as current assets if expected to be settled within twelve months, otherwise, they are classified as non-current.

b) Loans and receivables

Loans and receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. They are included in current assets, except for maturities greater than twelve months after the statement of financial position date, which are classified as non-current assets. Loans and receivables comprise loans, advances, deposits and other receivables and cash and cash equivalents in the statement of financial position.

c) Available-for-sale financial assets

Available-for-sale financial assets are non-derivatives that are either designated in this category or not classified in any of the other categories. They are included in non-current assets unless management intends to dispose of the investments within twelve months from the statement of financial position date.

d) Held to maturity

Financial assets with fixed or determinable payments and fixed maturity, where management has the intention and ability to hold till maturity are classified as held to maturity and are stated at amortized cost.

4.9.2 Recognition and measurement

All financial assets are recognized at the time when the Trust becomes a party to the contractual provisions of the instrument. Regular purchases and sales of investments are recognized on trade-date, the date on which the Trust commits to purchase or sell the asset. Financial assets are initially recognized at fair value plus transaction costs for all financial assets not carried at fair value through profit or loss. Financial assets carried at fair value through profit or loss are initially recognized at fair value and transaction costs are expensed in the income and expenditure account. Financial assets are derecognized when the rights to receive cash flows from the assets have expired or have been transferred and the Trust has transferred substantially all the risks and rewards of ownership. Available-for-sale financial assets and financial assets at fair value through profit or loss are subsequently carried at fair value. Loans and receivables and held to maturity investments are carried at amortized cost using the effective interest rate method.

MU

Gains or losses arising from changes in the fair value of the 'financial assets at fair value through profit or loss' category are presented in the income and expenditure account in the period in which they arise. Dividend income from financial assets at fair value through profit or loss is recognized in the income and expenditure account as part of other income when the Trust's right to receive payments is established.

Changes in the fair value of securities classified as available-for-sale are recognized in other comprehensive income. When securities classified as available-for-sale are sold or impaired, the accumulated fair value adjustments recognized in the fund are reclassified from the fund to income and expenditure account as a reclassification adjustment. Interest on available-for-sale securities calculated using the effective interest method is recognized in the income and expenditure account. Dividends on available-for-sale equity instruments are recognized in the income and expenditure account when the Trust's right to receive payments is established.

The fair values of quoted investments are based on current prices. If the market for a financial asset is not active (and for unlisted securities), the Trust measures the investments at cost less impairment in value, if any.

4.10 Financial liabilities

All financial liabilities are recognized at the time when the Trust becomes a party to the contractual provisions of the instrument.

A financial liability is derecognized when the obligation under the liability is discharged or cancelled or expired. Where an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as a derecognition of the original liability and the recognition of a new liability, and the difference in respective carrying amounts is recognized in the income and expenditure account.

4.11 Offsetting of financial assets and financial liabilities

Financial assets and financial liabilities are offset and the net amount is reported in the financial statements only when there is a legally enforceable right to set off the recognized amount and the Trust intends either to settle on a net basis or to realize the assets and to settle the liabilities simultaneously.

4.12 Impairment of financial assets - assets carried at amortized cost

The Trust assesses at the end of each reporting period whether there is objective evidence that a financial asset or group of financial assets is impaired. A financial asset or a group of financial assets is impaired and impairment losses are incurred only if there is objective evidence of impairment as a result of one or more events that occurred after the initial recognition of the asset (a 'loss event') and that loss event (or events) has an impact on the estimated future cash flows of the financial asset or group of financial assets that can be reliably estimated. Evidence of impairment may include indications that the debtors or a group of debtors is experiencing significant financial difficulty, default or delinquency in interest or principal payments, the probability that they will enter bankruptcy or other financial reorganization, and where observable data indicate that there is a measurable decrease in the estimated future cash flows, such as changes in arrears or economic conditions that correlate with defaults.

For loans and receivables category, the amount of the loss is measured as the difference between the asset's carrying amount and the present value of estimated future cash flows (excluding future credit losses that have not been incurred) discounted at the financial asset's original effective interest rate. The carrying amount of the asset is reduced and the amount of the loss is recognized in the income and expenditure account. If a loan or held to maturity investment has a variable interest rate, the discount rate for measuring any impairment loss is the current effective interest rate determined under the contract. As a practical expedient, the Trust may measure impairment on the basis of an instrument's fair value using an observable market price.

AN

If, in a subsequent period, the amount of the impairment loss decreases and the decrease can be related objectively to an event occurring after the impairment was recognized (such as an improvement in the debtor's credit rating), the reversal of the previously recognized impairment loss is recognized in the income and expenditure account.

4.13 Employees' benefits

4.13.1 Short term obligations

Liabilities for wages and salaries, including non-monetary benefits that are expected to be settled wholly within twelve months after the end of the period in which the employees render the related service are recognized in respect of employees' services up to the end of the reporting period and are measured at the amounts expected to be paid when the liabilities are settled. The liabilities are presented as current employee benefit obligations in the statement of financial position.

4.13.2 Post employment benefit - Defined contribution plan

A defined contribution plan is a post-employment benefit plan under which an entity pays fixed contribution into a separate entity and will have no legal or constructive obligation to pay further amounts. Obligations for contributions to defined contribution plans are recognized as an employee benefit expense in income and expenditure account when they are due. Prepaid contributions are recognized as an asset to the extent that a cash refund or a reduction in future payments is available.

4.13.3 Accumulating compensated absences

The Trust has a policy to provide employee benefits to its employees in the form of vesting accumulating compensated leave absences. As per SKMT's policy, employees are entitled to 24 days of paid leaves each year after completion of one year of service. The unused entitlement can be carried forward subject to the condition that the total unused accumulated leaves shall not exceed the prescribed limit i.e. 36 leaves. Any unused leaves in excess of the limit are lapsed and are not available for carry forward. Accumulated balance of unavailed earned leaves up to 36 shall be encashable at the rate of gross salary at the time of final settlement of an employee. Provisions are made annually to cover the obligation for accumulating compensated absences and are charged to income and expenditure account. The management is of the view that actuarial valuation will not result in any material adjustment to these financial statements. The liability has been accounted for on the basis that all employees leave at the reporting date.

4.14 Donations in kind

Land and properties received as donations are initially measured at the market value prevailing at the time of recognition of donation income. At subsequent reporting dates, these are remeasured at their fair value prevailing at the statement of financial position date and the difference in the fair values is charged/credited to income and expenditure account.

4.15 Stores and spares

Usable stores and spares are valued principally at weighted average cost. Items in transit are valued at cost comprising invoice value plus other charges incurred thereon.

4.16 Stocks

Stocks are valued principally at the lower of weighted average cost and net realizable value. Cost is arrived at on a moving average basis.

AM

Materials in transit are stated at cost comprising invoice value plus other charges incurred thereon.

Net realizable value signifies the estimated selling price in the ordinary course of operation less costs necessary to be incurred in order to make a sale. If the expected net realizable value is lower than the carrying amount, a write-down is recognized for the amount by which the carrying amount exceeds its net realizable value.

4.17 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term highly liquid investments with original maturities of three months or less, and bank overdrafts / short term borrowings. Bank overdrafts are shown within short term borrowings in current liabilities on the statement of financial position.

4.18 Trade and other payables

Trade and other payables are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. These are recognized initially at fair value and subsequently measured at amortized cost using the effective interest method.

4.19 Provisions

Provisions are recognized when the Trust has a present legal or constructive obligation as a result of past events, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate of the amount can be made. Provisions are reviewed at each statement of financial position date and adjusted to reflect the current best estimate.

4.20 Government grants

Grants from the government are recognized at their fair value where there is a reasonable assurance that the grant will be received and the Trust will comply with all the attached conditions.

Government grants relating to costs are deferred and recognized in the income and expenditure account over the period necessary to match them with the costs that they are intended to compensate.

Government grants relating to operating fixed assets are included in non-current liabilities as deferred government grants and are credited to the income and expenditure account on a straight-line basis over the expected lives of the related assets.

4.21 Income recognition

Income is recognized when it is probable that the economic benefits will flow to the entity and the income can be measured reliably. Income is measured at the fair value of the consideration received or receivable on the following basis :

-Donations received against depreciable assets are deferred as non-current liabilities and recognized as income when related expenses are incurred.

-Clinical income is recognized at the time when services are rendered.

-Zakat, donations and cafeteria income are recognized when received.

AU

-Return on deposits is accrued on a time proportion basis by reference to the principal outstanding and the applicable rate of return.

-Dividend income on equity investments is recognized as income when the right of receipt is established.

-Service revenue in respect of sale of software is recognized over the contractual period or as and when services are rendered to the customers.

4.22 Borrowings

Borrowings are recognized initially at fair value, net of transaction costs incurred. Borrowings are subsequently stated at amortized cost. Any difference between the proceeds (net of transaction costs) and the redemption value is recognized in the income and expenditure account over the period of the borrowings using the effective interest method. Finance costs are accounted for on an accrual basis and are reported under accrued markup to the extent of the amount remaining unpaid.

Borrowings are classified as current liabilities unless the Trust has an unconditional right to defer settlement of the liability for at least twelve months after the statement of financial position date.

4.23 Borrowing costs

General and specific borrowing costs directly attributable to the acquisition, construction or production of qualifying assets, which are assets that necessarily take a substantial period of time to get ready for their intended use or sale, are added to the cost of those assets, until such time as the assets are substantially ready for their intended use or sale.

Investment income earned on the temporary investment of specific borrowings pending their expenditure on qualifying assets is deducted from the borrowing costs eligible for capitalization. All other borrowing costs are recognized in the income and expenditure account in the period in which they are incurred.

4.24 Foreign currency transactions and translation

a) Functional and presentation currency

Items included in the financial statements of the Trust are measured using the currency of the primary economic environment in which the Trust operates (the functional currency). The financial statements are presented in Pak Rupees, which is the Trust's functional and presentation currency.

b) Transactions and balances

All monetary assets and liabilities in foreign currencies are translated into Pak Rupees at exchange rates prevailing at the statement of financial position date. Transactions in foreign currencies are translated into Pak Rupees at exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year end exchange rates of monetary assets and liabilities denominated in foreign currencies are charged or credited to income and expenditure account. Non-monetary assets and liabilities that are measured in terms of historical cost in a foreign currency are translated into Pak Rupees at exchange rates prevailing at the date of transaction. Non-monetary assets and liabilities denominated in foreign currency that are stated at fair value are translated into Pak Rupees at exchange rates prevailing at the date when fair values are determined.

AM

4.25 Expenses

Expenses are recognized in the income and expenditure account when incurred.

4.26 Deferred contributions

Restricted contributions are recognized as deferred contributions under non-current liabilities in the General Fund. These are recognized as income in the same period or periods as the related expenses are recognized.

4.27 Trade receivables

Trade debts are amounts due from recipients of services rendered in the ordinary course of business. They are recognized initially at invoice value, which approximates fair value, and subsequently measured at amortized cost using the effective interest method, less provision for impairment.

4.28 Contingent liabilities

Contingent liability is disclosed when:

- there is a possible obligation that arises from past events and whose existence will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the Trust; or

- there is present obligation that arises from past events but it is not probable that an outflow of resources embodying economic benefits will be required to settle the obligation or the amount of the obligation cannot be measured with sufficient reliability.

5. Revaluation reserve on land

This represents the surplus on revaluation of the following lands:

- donated to the Trust by the Government of Punjab for the purpose of construction of a cancer hospital, in Johar Town, Lahore;
- used for the diagnostic center at Jail Road, Lahore;
- donated to the Trust by the Government of Khyber Pakhtunkhwa for the purpose of construction of a cancer hospital, in Hayatabad, Peshawar;
- designated for the purpose of construction of a cancer hospital, in Bin Qasim Town, Education City, Karachi; and
- used for diagnostic centre in Defence Housing Authority, Karachi.

The revaluations had been done as at December 31, 2014 by an independent professional valuer on the basis of open market value. Revaluation is carried out at least after every five years to ensure that the carrying amount of assets does not differ materially from their fair value.

6. Operating fixed assets - owned

	Freehold land	Buildings on freehold land	Medical and surgical equipment	Support services equipment	Office equipment	HVAC and electrical equipment	Furniture and fixtures	Vehicles	Total
COST/REVALUED AMOUNT									
Balance as at January 1, 2017	2,168,004,700	3,159,454,724	3,205,915,650	321,720,140	391,100,397	1,372,635,928	113,269,492	88,191,657	10,820,302,688
Additions during the year	60,000,000	311,720,887	199,315,374	17,963,101	128,156,662	357,756,480	25,096,832	39,264,494	1,139,273,830
Disposals during the year	-	-	(5,004,573)	(1,419,200)	(791,590)	(32,629,092)	-	(17,085,071)	(57,279,526)
Balance as at December 31, 2017	2,228,004,700	3,471,175,611	3,399,828,451	338,273,041	518,465,459	1,697,763,316	138,366,324	110,421,080	11,902,298,992
Balance as at January 1, 2018	2,228,004,700	3,471,175,611	3,399,828,451	338,273,041	518,465,459	1,697,763,316	138,366,324	110,421,080	11,902,298,992
Additions during the year	-	236,456,237	1,828,616,907	54,414,131	94,927,904	92,975,536	37,931,021	18,704,250	2,364,025,985
Disposals during the year	-	-	(87,698,199)	(2,071,291)	(3,829,510)	(4,461,796)	(1,719,320)	(5,533,407)	(101,319,903)
Balance as at December 31, 2018	2,228,004,700	3,707,631,848	5,140,747,159	390,615,881	609,563,863	1,790,292,676	174,577,025	123,571,923	14,165,003,074
DEPRECIATION									
Balance as at January 1, 2017	-	467,889,454	2,043,935,343	217,144,213	236,192,311	411,461,669	40,974,491	50,361,361	3,467,957,842
Charge for the year	-	153,220,955	310,591,772	32,241,982	64,894,229	132,049,932	11,030,393	15,645,750	717,645,000
Depreciation on disposals	-	-	(3,821,369)	(1,064,275)	(767,498)	(32,573,129)	-	(16,794,851)	(55,021,107)
Balance as at December 31, 2017	-	621,109,409	2,350,675,732	248,321,920	298,319,042	510,938,481	52,004,874	49,212,260	4,130,581,738
Balance as at January 1, 2018	-	621,109,409	2,350,675,732	248,321,920	298,319,042	510,938,481	52,004,874	49,212,260	4,130,581,738
Charge for the year	-	162,757,945	398,223,635	26,716,043	88,165,314	162,101,727	14,137,193	18,710,455	870,811,962
Depreciation on disposals	-	-	(86,670,986)	(1,967,411)	(3,722,775)	(148,649)	(1,705,959)	(4,067,887)	(98,283,667)
Balance as at December 31, 2018	-	783,867,024	2,662,228,401	273,070,552	382,761,581	672,891,569	64,436,108	63,854,798	4,903,110,033
Book value as at December 31, 2017	2,228,004,700	2,850,066,202	1,049,152,699	89,951,121	220,146,427	1,186,824,835	86,365,450	61,208,820	7,771,715,254
Book value as at December 31, 2018	2,228,004,700	2,923,764,824	2,478,518,758	117,543,329	226,802,282	1,117,401,107	110,140,917	59,717,125	9,261,893,042
Annual depreciation rate %	5	15	15	15	20-33	10	10	20	

6.1 The cost of fully depreciated assets which are available for use as at December 31, 2018 is Rs 2,012.29 million (2017: Rs 1,862.48 million).

6.2 The depreciation charge for the year has been allocated as follows:

	2018	2017
Clinical expenses	-	-
General and administrative expenses	460,969,641	372,533,216
Marketing expenses	398,143,551	335,027,440
	11,698,800	10,064,347
	870,811,962	717,645,003

7. Intangible assets

	Cost as at January 1, 2018	Additions	Cost as at December 31, 2018	Amortization for the year	Accumulated amortization as on December 31, 2018	Book value as at December 31, 2018	Annual rate of amortization %
Computer software and licenses							
2018	48,525,066	23,655,190	72,180,256	18,775,024	37,806,762	34,373,494	33.3
2017	11,912,644	35,612,422	48,525,066	7,139,084	19,071,728	29,453,338	33.3

7.1 The amortization charge for the year has been allocated to general and administrative expenses.

AU

8. Assets subject to finance lease

					Rupees
	Medical and surgical equipment	Support services equipment	Furniture and fixtures	HVAC and electrical equipment	Total
COST					
Balance as at December 31, 2017	<u>101,018,351</u>	<u>13,507,238</u>	<u>1,740,832</u>	<u>174,660,521</u>	<u>290,926,942</u>
Balance as at December 31, 2018	<u>101,018,351</u>	<u>13,507,238</u>	<u>1,740,832</u>	<u>174,660,521</u>	<u>290,926,942</u>
DEPRECIATION					
Balance as at January 1, 2017	11,652,745	1,917,563	174,085	1,929,275	15,673,668
Charge for the year	15,274,833	2,315,482	179,083	17,466,052	35,235,450
Balance as at December 31, 2017	<u>26,927,578</u>	<u>4,233,045</u>	<u>353,168</u>	<u>19,395,327</u>	<u>50,909,118</u>
Balance as at January 1, 2018	26,927,578	4,233,045	353,168	19,395,327	50,909,118
Charge for the year	15,274,833	2,315,482	179,083	17,466,052	35,235,450
Balance as at December 31, 2018	<u>42,202,411</u>	<u>6,548,527</u>	<u>532,251</u>	<u>36,861,379</u>	<u>86,144,568</u>
Book value as at December 31, 2017	<u>74,090,773</u>	<u>9,274,193</u>	<u>1,387,664</u>	<u>155,265,194</u>	<u>240,017,824</u>
Book value as at December 31, 2018	<u>58,815,940</u>	<u>6,958,711</u>	<u>1,208,581</u>	<u>137,799,142</u>	<u>204,782,374</u>
Annual depreciation rate %	<u>15</u>	<u>15</u>	<u>10</u>	<u>10</u>	
				2018	2017
				Rupees	Rupees

8.1 The depreciation charge for the year has been allocated as follows:

Clinical expenses	- note 28	15,230,107	15,230,107
General and administrative expenses	- note 29	20,005,343	20,005,343
		<u>35,235,450</u>	<u>35,235,450</u>

ASU

9. Capital work-in-progress	2018 Rupees	2017 Rupees
Advances to suppliers	44,877,803	99,696,149
Civil works :		
- Patient Bed Lifts- SKMT Peshawar	-	37,856,200
- HVAC for MRI & CT Scan- SKMT Peshawar	175,000	-
- Radiation Bunker- SKMT Peshawar	14,618,793	38,616,019
- Research and Diagnostic centre- SKMT Karachi	65,540,945	-
- HVAC redesigning- SKMT Lahore	17,006,330	-
- Clinical Tower- SKMTLahore	19,079,094	-
	<u>116,420,162</u>	<u>76,472,219</u>
- note 9.1	<u>161,297,965</u>	<u>176,168,368</u>

9.1 The reconciliation of the carrying amount of capital work-in-progress is as follows:

Opening balance	176,168,368	480,686,258
Add: Additions during the year	307,418,314	492,590,824
Less: Transfers during the year	<u>322,288,717</u>	<u>797,108,714</u>
Closing balance	<u>161,297,965</u>	<u>176,168,368</u>

10. Long term loans and deposits

Loans to employees - unsecured and considered good	- note 10.1	29,695,962	30,053,670
Less: Current portion shown under current assets	- note 15	<u>12,166,719</u>	<u>11,379,442</u>
		17,529,243	18,674,228
Security deposits		<u>19,135,690</u>	<u>16,295,690</u>
		<u>36,664,933</u>	<u>34,969,918</u>

10.1 These represent un-secured interest free car loans given to employees. The car loans given are recoverable within a period of 4 years commencing from the date of disbursement through monthly deductions from salaries. These loans have not been carried at amortized cost as the effect of discounting is not considered material.

11. Long term investments	General fund Rupees	Endowment fund Rupees	2018 Rupees	2017 Rupees
Available-for-sale				
Hub Power Company Limited- quoted				
430,000 (2017: 430,000) fully paid ordinary shares of Rs 10 each				
Equity held 0.04% (2017: 0.04%)				
Market value - Rs 85.79 per share (2017: Rs 91 per share)	-	36,889,700	36,889,700	39,130,000
National Investment Trust				
23,372 (2017: 23,372) units				
Market value - Rs 63.39 per unit (2017: Rs 70.57 per share)	1,481,555	-	1,481,555	1,649,367
	<u>1,481,555</u>	<u>36,889,700</u>	<u>38,371,255</u>	<u>40,779,367</u>

12. Stocks

Medicines	261,688,297	242,902,576
Nursing and surgical supplies	167,818,256	128,049,638
Laboratory supplies	422,948,573	369,203,191
Others	<u>18,863,146</u>	<u>11,661,401</u>
	<u>871,318,272</u>	<u>751,816,806</u>

13. Donations in kind	2018 Rupees	2017 Rupees
Properties:		
House No. 44-A, Block-A, Satellite Town, Rawalpindi	140,737,775	140,215,000
49/1-B, Valancia Town, Lahore	34,338,884	31,360,000
House No. 29, Victoria Park, 60- Shahrah-e-Quaid-e-Azam, The Mall Lahore	17,026,460	24,111,000
Shop No. G-7, Ground Floor, Hassan Tower, Property No. 114-E-I, Gulberg Scheme No. 3, Lahore	16,350,000	11,990,000
House No. B-1-56, Aziz Street, Bhimber Road, Gujrat	14,251,600	10,093,000
Plot No. 108-B, Faisal Town, Lahore - note 13.3	7,500,000	7,500,000
Zamindar Hotel, Mcleod Road, Lahore - note 13.3	6,000,000	6,000,000
3-D Block-C, Samanabad, Lahore - note 13.3	5,500,000	5,500,000
132-E, Eden Cottages, Iqbal Park, Mouza Koray, Lahore Cantt	11,500,000	8,354,000
Khasra No. 471, Khata No. 193, Khatooni No. 675, Warsik Road, Peshawar - note 13.2	43,850,000	40,709,000
House No. 94, Street No. 7, Sector E-3, Phase-I, Hayatabad, Peshawar - note 13.2	26,811,000	17,939,000
Plot No. 486-C, Central Commercial Area, Block No. 2, P.E.C.H Society, Karachi - note 13.2	13,605,700	10,164,000
House No. 160-E, Eden Cottage Iqbal Park, Lahore - note 13.2	13,500,000	10,054,000
House No. 819, Street No.35, Sector D-4, Phase-1, Hayatabad, Peshawar - note 13.2	7,520,000	7,490,000
Khasra No. 58, Khata No. 1985/1988, Khatooni No. 2045, Scheme # 3 Civil Park, Tehsil Burewala, District Vehari - note 13.2	6,694,977	5,275,000
H. No I5 Street No. 25 Bhoond Pura, Momin Street Mozang, Lahore - note 13.2	7,620,000	4,373,000
House No. 263, Block 3, Quaid-e-Azam Scheme Township, Lahore - note 13.4	-	4,725,000
House No.39, Block- F, Fatima Jinnah Market, Karmabad Wahdat Road, Lahore	7,560,000	3,938,000
Office No. 09 & 09-A, 2nd Floor Davis Hytes, Davis Road, Lahore	1,479,600	2,154,000
House Khasra No. 1206, Khewat No. 1583, Garhi Awan, Hafizabad	1,746,000	1,726,000
Plot No. 4-A, Shop No 9, Pakistan Expatriates Coop. Housing Society Limited, Lahore - note 13.3	1,440,000	1,440,000
Plot No. 1563, Phase 2 in Jammu & Kashmir, Cooperative Housing Society, Kashmir Model Chakari Road, Rawalpindi - note 13.5	1,200,000	893,000
Shop No. 56, Mezzanine Floor, Land Mark Plaza, Jail Road, Lahore - note 13.5	446,600	308,000
Plot No. 32-A, Naz Town, Tehsil Model Town, Mouza, Sadhoki, Lahore - note 13.5	27,500,000	24,000,000
Plot No. 37 & 39, Street no. 13, Y block, Peoples Colony, Gujranwala	10,079,304	9,155,000
Plot No 382-E, Phase 9P DHA Lahore	9,000,000	8,500,000
Plot No 123-R, Phase 9P DHA Lahore	10,000,000	8,500,000
House No. 11 Street No. 5 Eden Palace Villas, Raiwand Road, Lahore - note 13.2	13,500,000	11,542,000
Plot No. 163-B, HAD's Kohsar Housing Scheme, Hyderabad	5,280,000	-
Plot No. 183, Block G-5, Wapda Employees Co-operative Housing Society, Lahore - note 13.2	11,970,000	-
	474,007,900	418,008,000
	108,589	-
	474,116,489	418,008,000
Less: Provision for unrealizable donations - note 13.3	20,440,000	20,440,000
	<u>453,676,489</u>	<u>397,568,000</u>

13.1 The Trust has recognized a net gain of Rs 43.47 million (2017: Rs 5.17 million) during the year on the revaluation of its properties carried out at year end by an independent professional valuer.

13.2 The titles of these properties are held in the name of SKMT, however the properties are currently occupied by donors under license agreements entered with SKMT, whereby the donors are allowed to occupy the property during their lifetime.

13.3 Provision for unrealizable donations	2018 Rupees	2017 Rupees
Opening balance	<u>20,440,000</u>	<u>20,440,000</u>
Closing balance	<u>20,440,000</u>	<u>20,440,000</u>

13.4 This property has been returned to the donor upon request with the approval of the Board of Governors of the Trust.

13.5 The titles of these properties are held in the name of the Chief Executive (Dr. Faisal Sultan) on behalf of the Trust.

14. Trade receivables	2018 Rupees	2017 Rupees
- Receivable from patients - considered good	5,780,930	7,559,910
- Corporate clients		
- considered good	65,738,339	49,974,781
- considered doubtful	564,086	564,088
	66,302,425	50,538,869
- Collection centers		
- considered good	108,868,180	100,035,098
- considered doubtful	-	3,035,594
	108,868,180	103,070,692
	180,951,535	161,169,471
Less: Provision for doubtful receivables - note 14.1	564,086	3,035,594
	<u>180,387,449</u>	<u>158,133,877</u>
14.1 Provision for doubtful receivables		
Opening balance	3,035,594	3,035,594
Less: Receivables written off	2,471,508	-
Closing balance	<u>564,086</u>	<u>3,035,594</u>

15. Loans, advances, deposits, prepayments and other receivables	General fund Rupees	Endowment fund Rupees	2018 Rupees	2017 Rupees
Current portion of long term				
loans to employees - note 10	12,166,719	-	12,166,719	11,379,442
Advances to employees	7,783,953	-	7,783,953	995,031
Advances to suppliers	22,415,175	-	22,415,175	44,214,991
Security deposits	8,170,658	-	8,170,658	-
Prepayments	8,071,615	-	8,071,615	6,984,968
Receivables against				
-Software sales	12,314,200	-	12,314,200	12,900,000
-Hide sales	7,951,082	-	7,951,082	13,219,606
-Qurbani campaign	-	-	-	13,707,214
Interest / mark-up receivable	7,685,002	64,230,015	71,915,017	74,611,771
Margin deposits against letters of credit	23,437,165	-	23,437,165	43,084,520
Income tax recoverable	17,401,860	2,476,085	19,877,945	17,646,219
Others	20,895,145	-	20,895,145	16,602,366
	<u>148,292,574</u>	<u>66,706,100</u>	<u>214,998,674</u>	<u>255,346,128</u>

		General fund Rupees	Endowment fund Rupees	2018 Rupees	2017 Rupees
16. Short term investments					
Held to maturity					
Term deposit receipts - note 16.1		315,341,738	2,428,514,670	2,743,856,408	3,183,223,873
Special sharika certificate- (Meezan Bank Limited)		-	-	-	200,000,000
Special saving certificates		-	-	-	82,171,017
Defence savings certificate - note 16.2		33,075,000	-	33,075,000	10,500,000
		<u>348,416,738</u>	<u>2,428,514,670</u>	<u>2,776,931,408</u>	<u>3,475,894,890</u>
Less : Provision against recoverability of investments - note 16.3		-	60,900,000	60,900,000	72,200,000
		<u>348,416,738</u>	<u>2,367,614,670</u>	<u>2,716,031,408</u>	<u>3,403,694,890</u>
Available-for-sale					
Shares in listed securities - note 16.4		833,617	-	833,617	921,543
		<u>833,617</u>	<u>-</u>	<u>833,617</u>	<u>921,543</u>
		<u>349,250,355</u>	<u>2,367,614,670</u>	<u>2,716,865,025</u>	<u>3,404,616,433</u>

16.1 Term deposit receipts (TDRs) are of the following banks:

- Trust Investment Bank Limited		-	60,900,000	60,900,000	61,700,000
- Habib Metropolitan Bank Limited - note 16.1.1		36,443,888	555,682,465	592,126,353	1,001,511,936
- Bank Alfalah Limited (including USD 3,842,628) (2017: USD 5,740,000)		-	570,888,241	570,888,241	633,122,000
- Bank Al-Habib Limited (including GBP Nil) (2017: GBP 19,945)		-	-	-	352,960,835
- United Bank Limited (including USD 5,357,487) (2017: USD 5,240,000)		278,897,850	742,547,698	1,021,445,548	577,972,000
- Faysal Bank Limited		-	498,496,266	498,496,266	555,957,102
	- note 16.1.2, 16.1.3 and	<u>315,341,738</u>	<u>2,428,514,670</u>	<u>2,743,856,408</u>	<u>3,183,223,873</u>

16.1.1 Included in these are TDRs of Rs 36.443 million (2017: Rs 34.323 million) in respect of Physicians Collegiality Fund as referred to in note 19.

16.1.2 These carry mark-up at coupon rates ranging from 5.90% to 10.45% (2017 : 5.75% to 6.85%) per annum for PKR TDRs.

16.1.3 These carry mark-up at coupon rates ranging from 2.05% to 5.00% (2017 : 1.70% to 2.45%) per annum for USD TDRs.

16.1.4 These carry mark-up at coupon rates at 1.65% (2017 : 1.60% to 1.65%) per annum for GBP TDRs.

16.2 Subsequent to the year end, the defence saving certificates were encashed, thereby the provision charged against this investment has been reversed during the year. The closing balance includes the principal and interest accrued on the principal till maturity amounting to Rs 2 million and Rs 31.07 million respectively.

AN

16.3 Provision against recoverability of investments has been recognized against the following investments :

	General fund Rupees	Endowment fund Rupees	2018 Rupees	2017 Rupees
Defence savings certificate - note 16.2	-	-	-	10,500,000
Trust Investment Bank Limited	-	60,900,000	60,900,000	61,700,000
- note 16.3.1	-	60,900,000	60,900,000	72,200,000

16.3.1 Movement in provision against recoverability of investments is as follows :

	General fund Rupees	Endowment fund Rupees	2018 Rupees	2017 Rupees
Opening balance	10,500,000	61,700,000	72,200,000	74,400,000
Less: Reversal of provision - note 16.2	10,500,000	800,000	11,300,000	2,200,000
Closing balance	-	60,900,000	60,900,000	72,200,000

16.4 Available-for-sale investments represent the investment in the following company :

Abbot Laboratories Limited- quoted

1,321 (2017: 1,321) fully paid

ordinary shares of Rs 10 each

Market value - Rs 631.05 per share

(2017: Rs 697.61 per share)

	833,617	-	833,617	921,543
--	---------	---	---------	---------

	General fund Rupees	Endowment fund Rupees	2018 Rupees	2017 Rupees
--	---------------------------	-----------------------------	----------------	----------------

17. Cash and bank balances

At banks :

On savings accounts - note 17.1 and 17.2				
- [including USD 97,309 (2017: USD 1,223,663)				
- and GBP 3,023,427 (2017: GBP 2,542,466)]	853,636,120	732,236	854,368,356	606,245,630
On current accounts				
- including AED 559,949 (2017: AED 96,181)	163,004,914	-	163,004,914	70,015,802
In deposit accounts - note 17.1	200,000,000	566,400,493	766,400,493	420,600,000
Cash in hand	26,769,140	-	26,769,140	27,791,014
Cheques and other instruments in hand	27,862,135	-	27,862,135	-
	<u>1,271,272,309</u>	<u>567,132,729</u>	<u>1,838,405,038</u>	<u>1,124,652,446</u>

17.1 The balances in savings accounts and deposit accounts bear mark up which ranges from 0.25% to 9.30% (2017: 0.25% to 6.65%) per annum and 9.10% to 10.45% (2017: 1.60% to 6.65%) per annum respectively.

M

17.2 These include balance amounting to Rs 0.25 million (2017: Rs 0.72 million) for physician's collegiality fund as disclosed in note 19.

		2018 Rupees	2017 Rupees
18. Current portion of non-current liabilities			
Current portion of long term loan- secured	- note 20	9,019,813	7,481,622
Current portion of liabilities against assets subject to finance lease	- note 21	79,281,408	104,826,850
		<u>88,301,221</u>	<u>112,308,472</u>
19. Trade and other payables			
Trade creditors		370,483,461	306,342,012
Bills payable		133,968,141	261,554,902
Accrued liabilities		159,898,634	131,047,933
Retention money payable		46,254,218	74,246,058
Clinical research fund		84,537,383	82,059,802
Advances from patients		127,881,630	41,912,750
Physician's collegiality fund		37,272,913	34,640,680
Withholding income tax payable		3,532,555	3,112,905
Withholding sales tax payable		4,136,447	2,166,217
Security deposits		36,808,064	34,129,300
Payable to provident fund	- note 35	24,945,531	5,744,534
Interest payable on long term loan- secured		276,741	250,265
Continuing Medical Education (CME) food fund		5,277,897	4,500,296
Advances from corporate customers		3,634,546	3,420,026
Others		6,921,464	7,025,334
		<u>1,045,829,625</u>	<u>992,153,014</u>
20. Long term loan - secured			
French protocol loan	- note 20.1	81,177,848	74,815,858
Less: Current portion shown under current liabilities	- note 18	9,019,813	7,481,622
		<u>72,158,035</u>	<u>67,334,236</u>

20.1 French protocol loan

	2018 (French Francs)	2017	2018 (Rupee equivalent)	2017	Rate of interest per annum	Number of installments payable
	3,326,076	3,695,642	81,177,848	74,815,858	1.4% payable semi annually	18 equal semi annual installments ending on November 7, 2027

The loan has been obtained by the Government of Pakistan from the French Government under Pak French Protocol and has been re-lent to the Trust. The loan comprises of 50% state credit and 50% commercial credit. Commercial credit has been fully repaid. The loan has been secured by way of a hypothecation charge on the medical and surgical equipment of the Trust in favour of the Government of Pakistan.

AK

	2018	2017
	Rupees	Rupees
21. Liabilities against assets subject to finance lease		
Present value of minimum lease payments	79,898,200	176,773,300
Less: Current portion shown under current liabilities - note 18	<u>79,281,408</u>	<u>104,826,850</u>
	<u>616,792</u>	<u>71,946,450</u>

The minimum lease payments have been discounted at an implicit interest rate of six month Karachi Inter Bank Offered Rate (KIBOR) plus 1% and payments are made on monthly basis. The implicit interest rate used to arrive at the present value of minimum lease payments ranges from 7.14% to 9.20% (2017: 6.99% to 7.36%) per annum. Since the implicit interest rate is linked with KIBOR, hence the amount of minimum lease payments and finance charge may vary from period to period. The asset will be transferred to lessee after successful completion of the lease term.

Taxes, repairs, replacements and insurance costs are to be borne by the lessee.

The amount of the future payment of the lease as shown in the statement of financial position and the period in which these payments will become due are as follows:

	Minimum lease payments	Future finance cost	Present value of lease liability	
			2018	2017
	Rupees	Rupees	Rupees	Rupees
Not later than one year	82,411,280	3,129,872	79,281,408	104,826,850
Later than one year and not later than five years	621,502	4,710	616,792	71,946,450
	<u>83,032,782</u>	<u>3,134,582</u>	<u>79,898,200</u>	<u>176,773,300</u>

22. Deferred liability

This represents provision for accumulating compensated absences. The reconciliation of the carrying amount is as follows :

	2018	2017
	Rupees	Rupees
Opening balance	105,071,908	73,579,554
Add: Provision for the year	32,662,165	52,110,541
Less: Payments during the year	16,289,722	20,618,187
Closing balance	<u>121,444,351</u>	<u>105,071,908</u>

23. Deferred contributions

This represent funds received for depreciable assets.

Contributions for depreciable operating fixed assets - note 23.1	<u>682,020,000</u>	<u>-</u>
--	--------------------	----------

23.1 Contributions for depreciable operating fixed assets

This comprises of amounts representing depreciable operating fixed assets of the Trust. If a depreciable asset is received in kind, an amount equal to the fair value of the donated asset is recognized directly in this head. Amortization is recognized accordingly to match the depreciation charge on the corresponding assets.

The reconciliation of the carrying amount is as follows :

	2018 Rupees	2017 Rupees
Opening balance	-	-
Add : Assets received during the year	707,280,000	-
Less: Amortization during the year- transferred to income - note 27	25,260,000	-
Closing balance	<u>682,020,000</u>	<u>-</u>

24. Deferred government grants

The reconciliation of the carrying amount is as follows:

Opening balance	162,402,200	118,750,000
Add : Additions during the year	-	49,902,200
Less : Amortization during the year - transferred to income - note 27	6,250,000	6,250,000
Closing balance - note 24.1	<u>156,152,200</u>	<u>162,402,200</u>

24.1 This represents the following government grants:

Grant of land for SKMT Peshawar - note 24.1.1	106,250,000	112,500,000
Grant of land for SKMT Karachi - note 24.1.2	49,902,200	49,902,200
	<u>156,152,200</u>	<u>162,402,200</u>

24.1.1 This represents the fair value of grant of land measuring 50 kanals located at Hayatabad, Phase V, Peshawar by the Government of Khyber Pakhtunkhwa ('GOKP') to develop, build and operate a cancer hospital. According to the Memorandum of Understanding ('MOU') signed between GOKP and the Trust, the Trust has developed the cancer hospital as per the terms of the MOU signed between GOKP and the Trust. Fair value of land was determined by an independent professional valuer. The conditions associated with grant have been met and the Trust will continue to comply with the conditions of the agreement in future.

24.1.2 This represents the fair value of grant of land measuring 20 acres located at Defence Housing Authority ('DHA') City Health Care District, Karachi to develop, build and operate a cancer hospital. According to the MOU signed between DHA and the Trust, the Trust has to develop the cancer hospital and the land cannot be used for any purpose inconsistent with the objectives of the Trust. Fair value of land was determined by an independent professional valuer.

25. Contingencies and commitments

25.1 Contingencies

- (i) The Trust purchased radiology, radiotherapy and operation theatre equipment financed by the French protocol loan and failed to make payments on the due dates resulting in penal interest of French Francs 1.624 million (2017: French Francs 1.624 million) equivalent to Rs 39.642 million (2017: Rs 32.877 million). No provision has been made in these financial statements as the management of the Trust is of the opinion that there are meritorious grounds that the liability is not expected to materialize.

AU

- (ii) Guarantees issued by banks on behalf of the Trust in favour of:
- (a) Sui Northern Gas Pipelines Limited amounting to Rs 73.06 million (2017: Rs 73.06 million).
- (b) The Inspector General Communications and IT, GHQ amounting to Nil (2017: Rs 2.2 million).

25.2 Commitments

- (i) Letters of credit in respect of capital expenditure Rs 230.83 million (2017: Rs 312.01 million).
- (ii) Letters of credit other than for capital expenditure Rs 166.25 million (2017: Rs 117.36 million).

25.3 Contractual commitments

- (i) Contractual commitments for SKMT Peshawar hospital as at December 31, 2018 are Rs 25.05 million (2017: Rs 174 million).
- (ii) Contractual commitments for SKMT Lahore hospital as at December 31, 2018 are Rs 10.53 million (2017: Nil).
- (iii) Contractual commitments for SKMT Karachi hospital as at December 31, 2018 are Rs 63.65 million (2017: Rs 24.64 million).

26. Clinical income	2018 Rupees	2017 Rupees
Diagnostic services	3,106,014,855	2,858,174,021
Treatment services	1,361,090,440	1,075,323,165
- note 26.1	<u>4,467,105,295</u>	<u>3,933,497,186</u>
26.1 Clinical income is net of the following:		
Gross income	11,516,794,985	10,142,534,005
Less: Waived as financial support to indigent patients		
- Radiology	629,831,520	542,292,251
- Nuclear medicine	105,633,275	117,735,920
- Pathology	1,083,755,600	1,020,320,701
- Medical oncology	627,310,714	528,725,223
- Radiation therapy	662,799,096	666,016,733
- Internal medicine	484,710,782	346,631,791
- Ancillary health services	12,895,677	12,462,350
- Surgery	1,223,732,221	989,297,010
- Pharmacy	1,522,227,226	1,371,637,830
	<u>6,352,896,111</u>	<u>5,595,119,809</u>
	5,163,898,874	4,547,414,196
Less: Discount to corporate clients	26,304,974	19,141,953
Clinical services charges	-	-
Commission to franchised collection centers	670,340,366	594,775,057
	<u>696,645,340</u>	<u>613,917,010</u>
Net income	<u>4,467,253,534</u>	<u>3,933,497,186</u>

AU

	General fund Rupees	Endowment fund Rupees	2018 Rupees	2017 Rupees
27. Other income				
Income from financial assets				
- Income from deposits and investments:				
Foreign currency	16,222,674	33,321,878	49,544,552	34,711,811
Local currency	78,218,942	95,229,770	173,448,712	152,860,535
- Exchange gain - net	157,041,187	259,463,229	416,504,416	134,101,881
- Reversal of provision against recoverability of investments - notes 16.2 and 16.3	10,500,000	800,000	11,300,000	2,200,000
	<u>261,982,803</u>	<u>388,814,877</u>	<u>650,797,680</u>	<u>323,874,227</u>
Income from non-financial assets				
- Donations	2,698,823,198	20,116	2,698,843,314	1,932,239,084
- Zakat	2,971,667,118	-	2,971,667,118	2,583,086,776
- Amortization of deferred contributions - note 23.1	25,260,000	-	25,260,000	-
- Gain on disposal of operating fixed assets - owned	1,116,908	-	1,116,908	8,001,613
- Sale of software	15,051,724	-	15,051,724	11,892,000
- Cafeteria sales	119,306,604	-	119,306,604	108,594,812
- Liabilities written back	6,931,827	-	6,931,827	19,800,380
- Revaluation gain on donations in kind - note 13.1	43,474,900	-	43,474,900	5,168,226
- Amortization of government grant - note 24	6,250,000	-	6,250,000	6,250,000
- Miscellaneous	12,034,740	2,537,000	14,571,740	14,043,145
	<u>5,899,917,019</u>	<u>2,557,116</u>	<u>5,902,474,135</u>	<u>4,689,076,036</u>
	<u>6,161,899,822</u>	<u>391,371,993</u>	<u>6,553,271,815</u>	<u>5,012,950,263</u>

		2018 Rupees	2017 Rupees
28. Clinical expenses			
Medicines and drugs		1,091,051,982	942,310,188
Pathology, nursing and other supplies		1,839,275,784	1,570,900,895
Salaries and benefits	- note 28.1	1,999,275,284	1,698,362,385
Consultants' fee		896,703,869	760,226,224
Utilities		284,693,662	210,454,655
Repairs and maintenance		259,317,402	277,344,614
Telephone, postage and courier		15,775,165	12,638,871
Printing, stationery and periodicals		13,598,833	8,939,114
Travelling and entertainment		8,076,965	7,871,501
Insurance		13,863,860	11,935,244
Recruitment and training		10,568,164	4,717,658
Subscriptions, legal and professional charges		13,028,992	2,260,129
Uniforms for staff		4,312,546	4,392,764
Outsourced medical services		42,144,589	21,995,711
Rent, rates and taxes		18,554,158	1,428,725
Depreciation on operating fixed assets - owned	- note 6.2	460,969,611	372,553,216
Depreciation on assets subject to finance lease	- note 8.1	15,230,107	15,230,107
Miscellaneous		243,460	43,006
		<u>6,986,684,433</u>	<u>5,923,605,007</u>

28.1 Salaries and benefits include Rs 71.48 million (2017: Rs 60.08 million) and Rs 22.02 million (2017: Rs 16.25 million) in respect of provident fund contributions by the Trust and accumulating compensated absences, respectively.

		2018	2017
		Rupees	Rupees
29. General and administrative expenses			
Food, laundry and other supplies		205,816,263	191,966,724
Salaries and benefits	- note 29.1	967,302,172	842,179,963
Utilities		191,749,481	217,660,405
Repairs and maintenance		220,031,583	155,206,463
Vehicle running		8,723,688	6,992,680
Telephone, postage and courier		13,330,813	13,354,136
Printing, stationery and periodicals		10,307,799	8,420,195
Travelling and entertainment		20,463,829	20,213,707
Insurance		10,909,668	9,746,979
Recruitment and training		7,938,896	8,762,696
Conferences and seminars		16,783,890	12,614,120
Uniforms for staff		2,297,123	2,382,182
Outsourced administrative services		61,482,231	34,802,151
Subscriptions, legal and professional charges		32,408,100	18,283,667
Rent, rates and taxes		8,279,943	6,573,500
Depreciation on operating fixed assets - owned	- note 6.2	398,143,551	335,027,440
Depreciation on assets subject to finance lease	- note 8.1	20,005,343	20,005,343
Other receivables written off		106,269	782,241
Assets written off		-	3,591,772
Amortization on intangible assets	- note 7.1	18,775,034	7,119,084
Miscellaneous		431,846	599,729
		<u>2,215,287,522</u>	<u>1,916,285,177</u>

29.1 Salaries and benefits include Rs 48.84 million (2017: Rs 42.14 million) and Rs 9.44 million (2017: Rs 14.84 million) in respect of provident fund contributions by the Trust and accumulating compensated absences, respectively.

29.2 Total number of employees at year end and average number of employees during the year are 3,117 (2017: 2,776) and 2,947 (2017: 2,676), respectively.

		2018	2017
		Rupees	Rupees
30. Marketing expenses			
Salaries and benefits	- note 30.1	144,983,921	120,294,362
Utilities		1,748,941	3,409,103
Repairs and maintenance		12,985,166	8,570,305
Telephone, postage and courier		16,243,607	9,344,091
Printing, stationery and periodicals		1,535,732	1,477,759
Travelling and entertainment		9,208,426	9,751,379
Advertisements, events and campaigns		605,197,327	391,343,373
Insurance		1,361,530	1,460,897
Recruitment and training		176,440	204,560
Subscriptions, legal and professional charges		13,091,010	9,985,366
Rent, rates and taxes		1,542,841	1,486,149
Depreciation on operating fixed assets - owned	- note 6.2	11,698,800	10,064,347
Miscellaneous		132,964	336,564
		<u>819,906,705</u>	<u>567,728,255</u>

30.1 Salaries and benefits include Rs 5.86 million (2017: Rs 4.79 million) and Rs 1.20 million (2017: Rs 0.40 million) in respect of provident fund contributions by the Trust and accumulating compensated absences, respectively.

31. Finance cost	General fund Rupees	Endowment fund Rupees	2018 Rupees	2017 Rupees
Interest / markup on:				
- Long term loan- secured	1,151,515	-	1,151,515	1,085,065
- Liabilities against assets subject to finance lease	10,085,023	-	10,085,023	15,839,914
Bank charges	7,700,647	-	7,700,647	7,170,028
	<u>18,937,185</u>	<u>-</u>	<u>18,937,185</u>	<u>24,095,007</u>

32. This represents return of donation in kind as stated in note 13.4.

33. As detailed in note 4.3, the income of the Trust is exempt from taxation.

34. Remuneration of key management personnel

Key management personnel are the persons having authority and responsibility for planning, directing and controlling the activities of the Trust. The aggregate amounts charged in the financial statements during the year in respect of remuneration, including certain benefits to the key management personnel of the Trust are given below:

	Chief Executive		Others	
	2018 Rupees	2017 Rupees	2018 Rupees	2017 Rupees
Managerial remuneration	21,015,096	20,526,272	54,693,313	49,712,502
Housing	-	-	21,877,325	19,885,001
Retirement benefits	1,576,132	1,539,470	6,152,998	5,592,656
Leave fair assistance/long service awards	1,751,258	-	6,858,032	6,621,509
Bonus	-	-	963,000	1,650,000
Utilities	-	-	5,469,331	4,971,250
Total	<u>24,342,486</u>	<u>22,065,742</u>	<u>96,013,999</u>	<u>88,432,918</u>
Number of persons	1	1	8	8

The Trust also provides the Chief Executive and other key management personnel with Trust maintained cars.

35. Transactions with related parties

The related parties comprise key management personnel and post employment contribution plan. Remuneration of key management personnel is disclosed in note 34 while the expense charged in the financial statements in respect of retirement contribution plan is Rs 126.12 million (2017: Rs 107.01 million). Moreover, the amount payable to provident fund has been disclosed under trade and other payables in note 19.

36. Financial risk management

36.1 Financial risk factors

The Trust's activities expose it to a variety of financial risks: market risk (including currency risk, interest rate risk and price risk), credit risk and liquidity risk. The Trust's overall risk management programme focuses on the unpredictability of financial markets and seeks to minimize potential adverse effects on its financial performance.

AN

Risk management is carried out by the Trust's Board of Governors (the Board). The Trust's finance department evaluates and hedges financial risks. The Board provides written principles for overall risk management, as well as written policies covering specific areas, such as currency risk, interest rate risk, credit risk, use of derivative and non-derivative financial instruments and investment of excess liquidity. All treasury related transactions are carried out within the parameters of these policies.

The Trust's overall risk management procedures to minimize the potential adverse effects of financial market on the Trust's performance are as follows :

a) Market risk

i) Currency risk

Currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. Currency risk arises mainly from future commercial transactions or receivables and payables that exist due to transactions in foreign currencies.

The Trust is exposed to currency risk arising from various currency exposures, primarily with respect to the United States Dollar (USD), Pound Sterling (GBP), Euro and UAE Dirham. Currently, the Trust's foreign exchange risk exposure is restricted to foreign currency investments, foreign currency bank balances, foreign currency loans and amounts receivable from/payable to the foreign entities.

At December 31, 2018 if the Rupee had weakened/strengthened by 5% against the USD with all other variables held constant, the impact on surplus for the year would have been Rs 64.15 million (2017: Rs 67.53 million) higher/lower respectively, mainly as a result of exchange gains/losses on translation of USD denominated financial instruments.

At December 31, 2018 if the Rupee had weakened/strengthened by 5% against the GBP with all other variables held constant, the impact on surplus for the year would have been Rs 26.58 million (2017: Rs 18.15 million) higher/lower respectively, mainly as a result of exchange gains/losses on translation of GBP denominated financial instruments.

At December 31, 2018 if the Rupee had weakened/strengthened by 5% against the French Francs with all other variables held constant, the impact on surplus for the year would have been Rs 4.06 million (2017: Rs 3.74 million) higher/lower respectively, mainly as a result of exchange gains/losses on translation of French Franc denominated financial instruments.

At December 31, 2018 if the Rupee had weakened/strengthened by 5% against the UAE Dirhams with all other variables held constant, the impact on surplus for the year would have been immaterial, mainly as a result of exchange gains/losses on translation of UAE Dirhams denominated financial instruments.

ii) Other price risk

Other price risk represents the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices (other than those arising from interest rate risk or currency risk), whether those changes are caused by factors specific to the individual financial instrument or its issuer, or factors affecting all similar financial instruments traded in the market. The Trust is not exposed to commodity price risk since it does not hold any financial instrument based on commodity prices. The Trust is exposed to equity securities price risk because of investments held by the Trust and classified as available-for-sale. To manage its price risk arising from investments in equity securities, the Trust diversifies its portfolio. Diversification of the portfolio is done in accordance with the limits set by the Board.

The Trust's investments in equity instruments of other entities are publicly traded on the Pakistan Stock Exchange Limited.



The table below summarizes the impact of increases/ decreases of the KSE-100 index on the Trust's surplus for the year and on fund balance. The analysis is based on the assumption that the KSE-100 index had increased / decreased by 10% with all other variables held constant and all the Trust's equity investments moved according to the historical correlation with the index :

	Impact on surplus for the year		Impact on other components of fund balance	
	2018	2017	2018	2017
	Rupees			
Pakistan Stock Exchange Limited	-	-	249,603	1,470,580

Surplus for the year would increase/decrease as a result of gains/ losses on equity securities classified as at fair value through profit or loss. Other components of fund balances would increase / decrease as a result of gains / losses on equity securities classified as available- for- sale. As at December 31, 2018, the Trust had no investments classified at fair value through profit or loss.

iii) Interest rate risk .

Interest rate risk represents the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates.

The Trust's interest rate risk arises from investments, long term loan, lease liabilities.

At the reporting date, the interest rate profile of the Trust's significant interest bearing financial instruments was:

	2018 Rupees	2017 Rupees
Fixed rate instruments		
Financial assets		
Short term investments	2,682,956,408	3,393,194,890
Bank balances - deposit and saving accounts	1,620,768,849	1,026,845,630
	<u>4,303,725,257</u>	<u>4,420,040,520</u>
Financial liabilities		
Less: Long term loan- secured	81,177,848	74,815,858
Net exposure	<u>4,222,547,409</u>	<u>4,345,224,662</u>
Floating rate instruments		
Financial assets	-	-
Financial liabilities		
Less: Liabilities against assets subject to finance lease	79,898,200	176,773,300
Net exposure	<u>(79,898,200)</u>	<u>(176,773,300)</u>

Au

Fair value sensitivity analysis for fixed rate instruments

The Trust does not account for any fixed rate financial assets and liabilities at fair value through profit or loss. Therefore, a change in interest rate at the reporting date would not affect the surplus of the Trust.

Cash flow sensitivity analysis for variable rate instruments

If interest rates on both financial assets and liabilities, at the year end date, had been 1% higher / lower with all other variables held constant, surplus for the year would have been Rs 1.29 million (2017: Rs 2.21 million) lower / higher, mainly as a result of higher / lower interest expense on floating rate instruments.

b) Credit risk

Credit risk represents the risk of financial loss being caused if counter party fails to discharge an obligation.

Credit risk of the Trust arises from certain investments, cash and cash equivalents and deposits with banks and financial institutions, as well as credit exposures to collection centers, corporate clients and patients, including outstanding receivables and committed transactions. The management assesses the credit quality of the collection centres, corporate clients and patients, taking into account their financial position, past experience and other factors. Individual risk limits are set based on internal or external ratings in accordance with limits set by the Board. The utilization of credit limits is regularly monitored and all transactions with these persons are settled in cash. For banks and financial institutions, only parties with a strong credit rating are accepted.

The Trust monitors the credit quality of its financial assets with reference to historical performance of such assets and available external credit ratings. The carrying values of financial assets are as under:

	2018 Rupees	2017 Rupees
Investments	2,755,236,280	3,445,395,800
Long term loans and deposits	36,664,933	34,969,918
Trade receivables	180,387,449	158,133,877
Loans, deposits and other receivables	133,412,821	142,420,399
Bank balances	1,783,773,763	1,096,861,432
	<u>4,889,475,246</u>	<u>4,877,781,426</u>

The carrying amount of financial assets represent the maximum credit exposure. The aging analysis of trade receivable balances is as follows:

	2018 Rupees	2017 Rupees
Upto 90 days	171,318,016	149,904,492
90 to 180 days	6,744,031	3,290,460
181 to 365 days	1,860,208	4,409,241
More than 365 days	465,194	529,684
	<u>180,387,449</u>	<u>158,133,877</u>

The management estimates the recoverability of trade receivables on the basis of financial position and past history of its customers based on the objective evidence that it will not receive the amount due from the particular customer. A provision for doubtful receivables is established when there is objective evidence that the Trust will not be able to collect all the amount due according to the original terms of the receivable. Significant financial difficulties of the debtors, probability that the debtor will enter bankruptcy or financial reorganization, and default or delinquency in payments are considered indicators that the trade debt is impaired. The provision is recognized in the income or expenditure account. The provision is written off by the Trust when it expects that it cannot recover the balance due. Any subsequent repayments in relation to amount written off, are credited directly to income or expenditure account.

Handwritten signature

The credit quality of Trust's bank balances can be assessed with reference to external credit ratings as follows:

	Ratings		Rating Agency	2018	2017
	Short term	Long term		Rupees	Rupees
Allied Bank Limited	A1+	AAA	PACRA	33,901,656	12,203,002
Askari Bank Limited	A1+	AA+	PACRA	2,405,378	959,998
Bank Alfalah Limited	A1+	AA+	PACRA	83,155,531	158,018,892
Bank Alfalah Limited Islamic Banking	A-1+	AA+	PACRA	58,165	69,971
Bank Al-Habib Limited	A1+	AA+	PACRA	539,479,164	376,960,321
Bank Islami Pakistan Limited	A1	A+	PACRA	1,097,024	404,424
Al-Baraka Bank (Burj Bank Limited)	A1	A	PACRA	54,300	82,202
Dubai Islamic Bank Limited	A-1	AA-	JCR-VIS	694,601	178,782
Al-Baraka Bank Limited	A1	A	PACRA	780,174	383,436
Faysal Bank Limited	A1+	AA	PACRA	483,899,203	16,706,493
First Women Bank	A2	A-	PACRA	293,893	207,946
Habib Bank Limited	A-1+	AAA	JCR-VIS	64,786,605	31,290,401
Habib Metropolitan Bank Limited	A1+	AA+	PACRA	260,593,141	703,753
Meezan Bank Limited	A-1+	AA+	JCR-VIS	214,563,424	243,280,613
MCB Bank Limited	A1+	AAA	PACRA	15,805,185	6,938,771
National Bank of Pakistan	A1+	AAA	PACRA	17,177,737	12,280,362
Silk Bank Limited	A-2	A-	JCR-VIS	235,234	155,240
Standard Chartered Bank (Pakistan) Limited	A1+	AAA	PACRA	25,887,272	3,619,830
Soneri Bank Limited	A1+	AA-	PACRA	368,870	308,880
Summit Bank Limited	A-1	A-	JCR-VIS	835,225	170,265
Telenor Microfinance Bank Limited	A-1	A+	PACRA	613,808	232,907
The Bank of Punjab	A1+	AA	PACRA	2,483,733	2,737,368
The Bank of Khyber	A1	A	PACRA	1,077,002	115,706
U Microfinance Bank Limited	A-2	A	JCR-VIS	64,444	121,692
United Bank Limited	A-1+	AAA	JCR-VIS	29,895,658	228,447,199
Mobilink Microfinance Limited	A1	A	PACRA	27,681	26,174
JS Bank Limited	A1+	AA-	PACRA	504,725	200,837
First Abu Dhabi Bank	Not available	Not available		3,001,421	-
Khushhali Bank Limited	A-1	A+	JCR-VIS	33,509	55,967
				<u>1,783,773,763</u>	<u>1,096,861,432</u>

Due to the Trust's long standing business relationships with these counterparties and after giving due consideration to their strong financial standing, management does not expect non-performance by these counter parties on their obligations to the Trust. Accordingly, the credit risk is minimal.

c) Liquidity risk

Liquidity risk is the risk that an entity will encounter difficulty in meeting obligations associated with financial liabilities.

Prudent liquidity risk management implies maintaining sufficient cash & marketable securities.

AM

Management monitors the forecasts of the Trust's cash and cash equivalents on the basis of expected cash flow. This is generally carried out in accordance with practice and limits set by the Trust. These limits vary by location to take into account the liquidity of the market in which the entity operates. In addition, the Trust's liquidity management policy involves projecting cash flows in each quarter and considering the level of liquid assets necessary to meet its liabilities, monitoring statement of financial position liquidity ratios against internal requirements and maintaining debt financing plans.

The table below analyses the Trust's financial liabilities into relevant maturity groupings based on the remaining period at the reporting date to the contractual maturity date. The amounts disclosed in the table are the contractual undiscounted cash flows as the impact of discounting is not significant.

	Rupees			
	Carrying amount	Less than one year	One to five years	More than five years
At December 31, 2018				
Long term loan- secured	81,177,848	9,019,813	36,079,254	36,078,781
Liabilities against assets subject to finance lease	79,898,200	79,281,408	616,792	-
Trade and other payables	1,045,829,625	1,045,829,625	-	-
	<u>1,206,905,673</u>	<u>1,134,130,846</u>	<u>36,696,046</u>	<u>36,078,781</u>
At December 31, 2017				
Long term loan- secured	74,815,858	7,481,622	29,926,487	37,407,749
Liabilities against assets subject to finance lease	176,773,300	104,826,850	71,946,450	-
Trade and other payables	992,153,014	992,153,014	-	-
	<u>1,243,742,172</u>	<u>1,104,461,486</u>	<u>101,872,937</u>	<u>37,407,749</u>

36.2 Fair value estimation

The fair value of traded investment is based on quoted market prices, except for tradable investments classified by Trust as "held to maturity". The table below analyses financial and non financial assets carried at fair value, by valuation method. The different levels have been defined as follows;

- Quoted prices (unadjusted) in active markets for identical assets or liabilities (Level 1).
- Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices) (Level 2).
- Inputs for the assets or liabilities that are not based on observable market data (i.e. unobservable inputs) e.g. estimated future cash flows. (Level 3).

	As at December 31, 2018			
	Level 1	Level 2	Level 3	Total
Financial assets measured at fair value				
Available-for-sale- Listed securities				
Long term investments	38,371,255	-	-	38,371,255
Short term investments	833,617	-	-	833,617
Non-financial assets measured at fair value				
Operating fixed assets (Freehold land)	-	2,228,004,700	-	2,228,004,700
Donations in kind	-	453,676,489	-	453,676,489
Total assets	<u>39,204,872</u>	<u>2,681,681,189</u>	<u>-</u>	<u>2,720,886,061</u>

As at December 31, 2017

	Rupees			Total
	Level 1	Level 2	Level 3	
Financial assets measured at fair value				
Available-for-sale- Listed securities				
Long term investments	40,779,367	-	-	40,779,367
Short term investments	921,543	-	-	921,543
Non-financial assets measured at fair value				
Operating fixed assets (Freehold land)	-	2,228,004,700	-	2,228,004,700
Donations in kind	-	397,568,000	-	397,568,000
Total assets	41,700,910	2,625,572,700	-	2,667,273,610

The trust's policy is to recognize transfers into and out of different fair value hierarchy levels at the date the event or change in circumstances that cause the transfer occurred. There were no transfers between level 1 and 2 & level 2 and 3 during the year and there were no changes in valuation techniques during the year:

Valuation techniques and inputs used in determination of fair values

Items	Valuation techniques and input used
Investment in listed securities	Fair value of investments in listed securities are valued on the basis of closing quoted market prices available at the Pakistan Stock Exchange.
Operating fixed assets (Freehold land)	Fair value of freehold land has been derived using a sales comparison approach. Sale prices of comparable land in close proximity are adjusted for differences in key attributes such as location and size of the property. The most significant input into this valuation approach is price per square foot.
Donations in kind	Fair value of properties received as donations in kind has been derived using a sales comparison approach. Sale prices of comparable properties in close proximity are adjusted for differences in key attributes such as location and size of the property. The most significant input into this valuation approach is price per square foot.

36.3 Financial instruments by categories

	Available- for- sale	Held to maturity	Loans and receivables	Total
	Rupees			
As at December 31, 2018				
Assets as per statement of financial position				
Long term investments	38,371,255	-	-	38,371,255
Long term loans and deposits	-	-	36,664,933	36,664,933
Trade receivables	-	-	180,387,449	180,387,449
Loans, deposits and other receivables	-	-	133,412,821	133,412,821
Short term investments	833,617	2,716,031,408	-	2,716,865,025
Bank balances	-	-	1,783,773,763	1,783,773,763
	39,204,872	2,716,031,408	2,134,238,966	4,889,475,246

As at December 31, 2018

Financial liabilities at amortized cost
Rupees

Liabilities as per statement of financial position

Long term loan	81,177,848
Liabilities against assets subject to finance lease	79,898,200
Trade and other payables	1,045,829,625
	<u>1,206,905,673</u>

As at December 31, 2017

	Available- for- sale	Held to maturity	Loans and receivables	Total
Rupees				
Assets as per statement of financial position				
Long term investments	40,779,367	-	-	40,779,367
Long term loans and deposits	-	-	34,969,918	34,969,918
Trade receivables	-	-	158,133,877	158,133,877
Loans, deposits and other receivables	-	-	255,346,128	255,346,128
Short term investments	921,543	3,403,694,890	-	3,404,616,433
Bank balances	-	-	1,096,861,432	1,096,861,432
	<u>41,700,910</u>	<u>3,403,694,890</u>	<u>1,545,311,355</u>	<u>4,990,707,155</u>

As at December 31, 2017

Financial liabilities at amortized cost
Rupees

Liabilities as per statement of financial position

Long term loan	74,815,858
Liabilities against assets subject to finance lease	176,773,300
Trade and other payables	992,153,014
	<u>1,243,742,172</u>

36.4 There are no significant financial assets and financial liabilities that are subject to offsetting, enforceable master netting arrangements and similar agreements.

37. Corresponding figures

Corresponding figures have been re-arranged, wherever necessary, for the purpose of comparison. However, no significant reclassifications have been made.

38. Date of approval of financial statements

These financial statements were authorized for issue on May 19, 2019 by the Board of Governors of the Trust.

AK

[Signature]
Member

[Signature]
Member



A man with dark hair and a beard, wearing a white shirt, is seated at a desk in an office. He is looking down and writing on a document with a pen. The desk is cluttered with papers and a clear plastic file holder. In the background, other office workers are visible, and the environment appears to be a busy administrative or service center. A large, semi-transparent orange rectangle is overlaid on the center of the image, containing the text "CONTACT INFORMATION" in white, bold, uppercase letters.

CONTACT INFORMATION

REGIONAL OFFICES

Lahore

Shaukat Khanum Memorial Cancer Hospital and Research Centre
7A Block R-3
M.A. Johar Town, Lahore
Tel: +92 42 3590 5000
Fax: +92 42 3594 5208
UAN: 111 155 555
Toll-free: 0800 11555

Peshawar

Shaukat Khanum Memorial Cancer Hospital and Research Centre
5-B, Sector A-2,
Phase-5, Hayatabad
Peshawar
Pakistan
Tel: +92 91 588 5000
Fax: +92 91 582 3815
UAN: 111-155-555
Toll-free: 0800 11555
Email: fundraising@skm.org.pk

Karachi

Shaukat Khanum Regional Office
Karachi Diagnostic Centre and Clinic
Plot DDCH1, 1st Street
Phase VII Extension DHA
Karachi, Pakistan
Tel: +92 21 3587 2573, +92 21 3530 6363
UAN: 111 756 756
Toll-free: 0800 11555
Email: fundraising@skm.org.pk

Islamabad

Shaukat Khanum Regional Office
2 Royal Centre, Fazal-e-Haq Road
Blue Area, Islamabad
Tel: +92 51 234 8275
Fax: +92 51 234 8278
UAN: 111 155 555
Toll-free: 0800 11555
Email: fundraising@skm.org.pk

Multan

Shaukat Khanum Regional Office
Hotel Ramada, 76-Abdali Road
Multan, Pakistan
Tel: +92 61 4783344
Toll-free: 0800 11555
Email: fundraising@skm.org.pk

Faisalabad

Shaukat Khanum Regional Office
Office # 105, Mezzanine Floor
Centre Point Plaza, Jaranwala Road
Faisalabad
Contact: +92 300 8401448
Toll-free: 0800 11555
Email: fundraising@skm.org.pk

Sialkot

Shaukat Khanum Regional Office
Soni Square
Khadim Ali Road
Sialkot
Tel: +92 52 3258326
Toll-free: 0800 11555
Email: fundraising@skm.org.pk

SKMT OVERSEAS OFFICES

United Kingdom

Imran Khan Cancer Appeal
PO Box 786
66 Little Horton Lane
Bradford, BD5 0YE, UK
Tel: +44 1274 424 444
Email: info@ikca.org.uk
Website: <https://www.ikca.org.uk>

United States of America

Imran Khan Cancer Appeal Inc,
4 Forest Park Dr.
Farmington, CT 06032, USA
Tel: +1 (860) 674 8865 (9 am to 1 pm EST)
Fax: +1 (860) 674 9007
Email: shkm2@sbcglobal.net

Canada

Cancer Education Research Foundation
7800 Kennedy Road
Suite # 101
Markham, Ontario, L3R 2C7
Tel: +1 905 470 8111
Fax: +1 905 470 8121
Email: donation@cerfcanada.com
Website: www.cerfcanada.com

Australia

Shaukat Khanum Memorial
Cancer Foundation Limited
Suite 12, Level 1
89 Jones Street, ULTIMO
Sydney NSW 2007
Tel: + 61 2 9211 8465
Email: info@skmcf.org.au
Website: www.shaukatkhanum.org.au

United Arab Emirates

Shaukat Khanum Memorial Trust
P. O. Box 506032
Office No. 112, Building No. 4 (Floor No.1)
International Humanitarian City,
Corporate Offices in Dubai Industrial City,
Dubai, UAE
Office: +971 4 457 2434
Mobile: +971 50 260 2503
Email: skmtgulf@skm.org.pk

NORWAY

Friends of Shaukat Khanum in Scandinavia,
Høgåsveien 104, 1259
Oslo, Norway.
Tel: + 47 930 63 545
Email: norway@skm.org.pk

WALK-IN CLINICS

Lahore

Shaukat Khanum Memorial Cancer Hospital and
Research Center
7-A Block R-3
Johar Town, Lahore
Phone: +92 42 3590 5000 Ext. 8888, 3435
Fax: +92 42 3594 5144
Email: outpatient@skm.org.pk
Hours of Operation: 8:00 am to 5:00 pm Monday
through Saturday.
Closed on Sunday and Public Holiday
Tokens are issued from 8:00 am to 4:00 pm

Karachi

Karachi Diagnostic Centre & Clinic
Plot DDCH-1, 1st Street,
Phase-VII Extension, DHA, Karachi
Phone: +92 21 111 756 756
Fax: +92 021 35318512
Email: kdcmanager@skm.org.pk
Hours of Operation: 8:00 am to 5:00 pm Monday
through Friday
Closed on Saturday, Sunday & Public Holiday
Tokens are issued from 8:00 am to 4:00 pm

Peshawar

Shaukat Khanum Memorial Cancer Hospital and
Research Center
5-B, Sector A-2,
Phase-5, Hayatabad
Peshawar
Phone: +92 91 588 5000 Ext. 3781, 3782

Multan

Shaukat Khanum Walk-in Clinic
319-Sher Shah Road,
Near Dera Adda Chowk, Multan
Phone: +92 061 4782251-2
Fax: +92 061 4503305
Email: skdcmanager@skm.org.pk
Hours of Operation: 8:00 am to 5:00 pm Monday
through Friday
Closed on Saturday, Sunday & Public Holiday
Tokens are issued from 8:00 am to 4:00 pm

LABORATORY COLLECTION CENTRES

Shaukat Khanum Memorial Cancer Hospital and Research Centre has an extended nationwide network of laboratory collection centres running under strict guidelines and standard operating procedures to ensure provision of quality testing services to people all over Pakistan. An advanced patient data management system is available where test results are saved within the Hospital's Information System, an in-house built software system, and can be easily accessed online.

Abbottabad

Shop No 4 & 5, Time Square
Opposite INOR Hospital, Mansehra
Road
Abbottabad
CC 45
Tel: +92 992 518909
Fax: +92 992 385865

Shop No. 7, Opp. Income Tax Office
Mansehra Road.
Abbottabad
CC 47
Tel: +92 99 234 1529

Arifwala

Near THQ Hospital, Qaboola Road
Arifwala
CC 83-A
Tel: +92 457 835768

Attock

Shop No. 1, Fowara Chowk
Civil Bazar, Near The Bank of
Punjab
Attock
CC 82
Tel: +92 57 270 1077
Fax: +92 57 261 0108

Bahawalnagar

Baldia Road, Commercial College
Chowk
Opposite Caltex Petrol Pump
Bahawalnagar
CC 96
Tel: +92 63 227 7752

Opposite OPD Gate Bahawal
Victoria Hospital
Circular Road, Bahawalpur
CC 200
Tel: +92 62 2501251

Bannu

CC 132A Opposite Khalifa Gul
Nawaz Hospital Gate No 1, Township

Bannu, Opposite Gate No.2, DHQ
Teaching Hospital
D.I.Khan Road
Bannu
CC 132
Tel: +92 928 610024

Batkhela

Opposite Shell Petrol Pump
GT Road
Batkhela
CC 128
Tel: +92 932 410100

Bhakkar

Shop No. 1,2, Near Abdullah
Hospital
Club Road
Bhakkar
CC 204
Tel: +92 453 512686

Bhalwal

Main Bazar opp. Municipal
Committee Office
Bhalwal
CC 153-A
Tel: +92 48 6644123

Buner

Shop No. 1 & 2, Mira Khan Plaza
Dagar Pull
Buner
CC 161
Tel: +92 093-9510537

Burewala

Shop No.58, Al-Yaqeen Trade Centre

Opposite Stadium Road
Burewala
CC 85
Tel: +92 67 3771759
Fax: +92 67 3771759

Chakwal

Shop # 1, Haral Market
Near Sui Gas Office
Opposite Government Post
Graduate College
Rawalpindi Road
Chakwal
CC 203
Tel: +92 543 553261

Charsadda

Haji Kifayat Ullah Market
Mardan Road
Charsadda
CC 210
Tel: +92 91 6515700

Chichawatni

Shop No.1954, Street No.6
Block No.13, Crescent Girls College
Road
Chichawatni
CC 131
Tel: +92 040 5482020

Chiniot

Shop No. 1-2, Syed Building
Adjacent Shaukat Medicare, Jhang
Road
Chiniot
CC 149
Tel: +92 47 6333370

Chishtian

High Way Road
Mulhiqa Sadar Eidgah
Chishtian
CC 138
Tel: +92 63 250 1111

Daska

Shop No. 21, Cooperative Market
Complex, near THQ Hospital,
Circular Road
Daska
CC 62
Tel: +92 52 6615498

Dera Ghazi Khan

4 – Jinnah Medical Complex
Near DHQ Hospital, Railway Road
Dera Ghazi Khan
CC 31
Tel: +92 64 2473731
Fax: +92 64 2473732

Dera Ismail Khan

Shop No. 8, Near Rauf Centre
Opposite D.H.Q. Hospital
Dera Ismail Khan
CC 78
Tel: +92 966 719903
Fax: +92 966 719904

Depalpur

Syed Plaza, Kasur Road
Near General Bus Stand
Depalpur
CC 64-A
Tel: +92 444 540567

Faisalabad

88 – Iqbal Stadium
Faisalabad
CC 4
Tel: +92 41 2616243-44
Fax: +92 41 2616245

17- A, Peoples Colony
Opposite Radio Pakistan, D-
Ground
Faisalabad
CC 10
Tel: +92 41 8735343
Fax: +92 41 8735344

101-CZZ Susan Road Madina Town
Faisalabad
CC 10-A
Tel: +92 41 8503342

479 – Main Gulberg Road
Faisalabad
CC 22
Tel: +92 41 2602664

Fax: +92 41 2636289
Adjacent Khalid Service Station
Aminabad No. 2, Main Samanabad
Road
Faisalabad
CC 68
Tel: +92 41 2562664
Fax: +92 41 2562665

Plot No. 16-206 Kashmir Bridge
West Canal Road, Amin Town
Faisalabad
CC 69
Tel: +92 41 8751943
Fax: +92 41 8751944

Bhatti Market, Near Allied School
Sargodha Road
Faisalabad
CC 139
Tel: +92 41 878 2664

Gojra

Opposite Jinnah Park
Tehsil Office Road
Gojra
CC 134
Tel: +92 46 3515006

Gujar Khan

Shop No. B-1-422, New Barki
G.T Road
Gujar Khan
CC 216
Tel: +92 51 3515817

Gujranwala

62 – Jinnah Stadium Shopping
Complex
Civil Lines
Gujranwala
CC 3
Tel: +92 55 3250014
Fax: +92 55 3255530

Sugar Mill Chowk
G.T Road. Rahwali Cantt,
Gujranwala
CC 43
Tel: +92 55 3865800

Main Market, Near Kashmir Road
Chowk
Peoples Colony
Gujranwala
CC 93
Tel: +92 55 4555050

Fax: +92 55 4555050

291-A Main Market
Model Town
Gujranwala
CC 136
Tel: +92 55 3850014

Near Islamia College, College Road
Gujranwala
CC 145
Tel: +92 55 4230008

Jinnah Super Market
Link Road, WAPDA Town
Gujranwala
CC 150
Tel: +92 55 4283090

Gujrat

Mehmoda Chowk
Near Aziz Bhatti Shaheed Hospital,
Bhimbar Road
Gujrat
CC 8
Tel: +92 53 3605473
Fax: +92 53 3605164

Shop No.2, Nadir Trade Center
Near Fawara Chowk, Circular Road
Gujrat
CC 116
Tel: +92 53 3537878
Fax: +92 53 3537979

Hafizabad

Near District Civil Hospital
Raja Chowk, Kolo Tarar Road
Hafizabad
CC 112
Tel: +92 547 522226

Haripur

Shop No. 4, Shoaib Market
Opposite Yahya Welfare Trust, GT
Road
Haripur
CC 67
Tel: +92 995 611294
Fax: +92 995 611295

Haroonabad

Bangla Road
Opposite THQ Main Gate
Haroonabad

CC 207
Tel: +92 63 2252111

Hasilpur

Shop No. 1 and 2, Hospital Road
Besides Allama Iqbal Park
Hasilpur
CC 173
Tel: +92 62 2443402

Islamabad

2 – Royal Centre
106 – West Fazal-e-Haq Road, Blue
Area
Islamabad
CC 19
Tel: +92 51 2348276
Fax: +92 51 2348277

Shop No. 11, Omer Plaza
F-8 Markaz
Islamabad
CC 127
Tel: +92 51 2817009

Jaranwala

Shop No. P – 200, Old Safdar Hotel
Opposite Fazal Ilahi Chatta Hospital
Faisalabad Road
Jaranwala
CC 148
Tel: +92 41 4311328
Fax: +92 41 4311329

Jauharabad

Opposite Raja Sarfaraz Hospital
College Road
Jouharabad
CC 167
Tel: +92 454 721122

Jhang

Opposite DHQ Hospital
Gojra Road
Jhang
CC 97
Tel: +92 477 621183
Fax: +92 477 621184

Jhelum

Shop No. 2, Ground Floor
Dar-ul-Aloom, Machine Mohallah
No. 1
Jhelum

CC 53
Tel: +92 544 620642
Fax: +92 544 620652

Kamalia

Main Zeeshan Colony Road
Near HBL Bank
Kamalia
CC 159
Tel: +92 46 3411012

Kamoke

Near Masjid Siddique Adday Wali
Opposite Ghala Mandi
G.T. Road, Kamoke
CC 66-A
Tel: +92 55 6810018

Karachi

Plot DDCH1, 1st Street
Phase VII Extension DHA
Near Qayyumabad
Karachi, Pakistan

CC 28
Tel: +92 21 3531 8495-99 or +92 21
3531 8513-16
Fax: +92 21 3531 8512
UAN: 111 756 756

Shop No. 1, Opposite S.S tower
Adjacent Hill Park Hospital
Shaheed-e-Millat Road, Karachi
CC 175
Tel: +92 333 0326906

Plot No A-1, Sector Z-5
Gulshan-e-Maymar
Karachi
CC 176
Tel: +92 333 0326901

Shop No 3/14, Block C/II
Near Abbasi Shaheed Hospital
Karachi
CC 177
Tel: +92 333 0326903

Shop No 6, 7, Opposite Aladin
Amusement Park
Main Rashid Minhas Road
Karachi
CC 178
Tel: +92 333 0326908

Shop No. M-3, Al-Azam Square
Sharif Abad, FB Area, Block No 1

Karachi
CC 179
Tel: +92 333 0326902

Shop No. 8 & 9, Zahra Square
Block 6, Gulshan-e-Iqbal
Karachi
CC 180
Tel: + 92 333 0326910

Shop No. 2, C-19, Block 4
(Nasirabad) F. B. Area
Karachi
CC 186
Tel: +92 333 0326913

Shop No. 9, Street 5
Al Ismailia Charitable Society (Near
Karimabad Bridge)
F. B. Area, Block 14
Karachi
CC 187
Tel: +92 333 0326912

Shop No. 12 & 13, Ground Floor
Marine Arcade Opp. BBQ Tonight,
Com 1-A
Shahrah-e-Firdousi, Block 3, Clifton
Karachi
CC 188
Tel: +92 333 0326927

Shop No. 2 & 3, Ground Floor
Plot No. 2 C, Street 7
Badar Commercial Area, Phase V
Ext. DHA
Karachi
CC 189
Tel: +92 333 0326928

Shop No. 1 to 5, Ground Floor
N-40, Korangi No 3 ½,
Main Korangi Road
Karachi
CC 190
Tel: +92 333 0326930

Shop No. 2, Ground Floor
Moti Wala Centre, Plot No C-27
Main Khayaban-e-Sehar, Phase VII,
DHA
Karachi
CC 191
Tel: +92 333 0326921

Shop No. 10 & 11, Ground Floor
Rehman Plaza, Depot Lines
Link M.A. Jinnah Road near OMI
Karachi
CC 192

Tel: +92 333 0326926

Shop No. 1 & 2, Ground Floor
Plot No 2-C B/1
Al-Falah Housing Society
Shah Faisal Colony
Karachi
CC 193
Tel: +92 333 0326931

Shop No. 1, Plot No S-02/794
Saoodabad, Malir
Karachi
CC 195
Tel: +92 333 0326922

Shop No. 1, Plot No 22-C
Street 26, Khayaban-e-Touheed
Phase V Ext., DHA,
Karachi
CC 196
Tel: +92 333 0326925

Shop No. 2, Plot No 27-E
Main Khayaban-e-Jamie
Phase II Ext., DHA
Karachi
CC 197
Tel: +92 333 0326923

Shop No. 3, Plot No 31-C
Stadium Lane No 1, Phase V, DHA
Karachi
CC 198
Tel: +92 333 0326924

Shop No. 3, Plot No 39-C, Lane No 7
Khayaban-e-Ittehad Commercial,
Phase VI, DHA
Karachi
CC 199
Tel: +92 333 0326932

Shop No 514, 5th Floor, Doctor
Plaza
Near Do Talwar,
Main Clifton Block – 9
Karachi
CC 211
Tel: +92 333 0326933

Shop # 4, Plot # 14/1, Sheet # R-C-1,
Chand Bibi Road Off Civil Burns
Ward
Karachi
CC 217
Tel: +92 333 0326934

Kasur

Shop No. 1, Lilyani Adda

Railway Road
Kasur
CC 105
Tel: +92 49 2720166
Fax: +92 49 2720186

Khanewal

Shop No.1, Street No.1, Block No.16
Near Siddique Hospital, Stadium
Road
Khanewal
CC 81
Tel: +92 65 2551152
Fax: +92 65 2551152

Khanpur

Shop No. 387, Model Town B
Kacheri Road
Khanpur
CC 163
Tel: +92 68 5955586

Kharian

Shop No. 2, Al-Moqueet Trade
Centre
G.T Road, Kharian
CC 121
Tel: +92 53 7600521

Kohat

Nadeem Shinwari Market
Opp. Awami Paint Hangu Road
Kohat
CC 49-A
Tel: +92 922 517422

Kot Addu

New Zain Plaza, Adjacent THQ
Hospital
Kot Addu
CC 71-A
Tel: +92 066 2240 858

Lahore

89-G, Jail Road
Lahore, Pakistan
CC 1
Tel: +92 42 35905000 Ext: 3453
UAN: +92 (42) 111 756 756
Fax : +92 42 35408268
E-mail: skdcmanager@skm.org.pk

155-A, HBFC
Opposite Jinnah Hospital
Lahore

CC 2
Tel: +92 42 35162767
Fax: +92 42 35160741

22 Pak Block, Main Boulevard
Allama Iqbal Town
Lahore
CC 11
Tel: +92 42 37811743
Fax: +92 42 37811744

18-A, Wahdat Road
Opposite Abrar Business Centre
Lahore
CC 86
Tel: +92 42 35887927
Fax: +92 42 35861363

858-N, Poonch Road
Samanabad
Lahore
CC 87
Tel: +92 42 37537090
Fax: +92 42 37537092

159 – Iqbal Park
Main Boulevard, Defence Housing
Authority
Lahore Cantt, Lahore
CC 14
Tel: +92 42 35890643
Fax: +92 42 35890644

19 – Rattan Chand Road
Opposite Mayo Hospital
Lahore
CC 17
Tel: +92 42 37240337
Fax: +92 42 37240338

82-A, Naseerabad
Main Ferozpur Road
Lahore
CC 21
Tel: +92 42 35842101
Fax: +92 42 35842102

Shop No.7, Mughal Market, Near
New
Emergency Gate, Lahore General
Hospital
Main Ferozpur Road
Lahore
CC 88
Tel: +92 42 35807044

55-1-B-1, Peco Road
Township, Near Mochi Pura Stop
Lahore

CC 23
Tel: +92 42 35119713
Fax: +92 42 35717498

19 – Sanda Road
Lahore
CC 15
Tel: +92 42 37171449
Fax: +92 42 37171450

19-E, Zohra Heights
Main Market, Gulberg II
Lahore
CC 27
Tel: +92 42 35877467, 35710520
Fax: +92 42 35875134

1502-A/1, Zarar Shaheed Road
Lahore Cantt.
Lahore
CC 29
Tel: +92 42 36650990
Fax: +92 42 36650330

114-Allama Iqbal Road
Near Ehsaan Centre, Garhi Shahu
Lahore
CC 36
Tel: +92 42 36315573
Fax: +92 42 36315573

43 – Main Ravi Road
Lahore
CC 40
Tel: +92 42 37708955
Fax: +92 42 37708933

Plot No. 1, Block-K, Phase-1
Defence Housing Authority
Lahore
CC 48
Tel: +92 42 35709867
Fax: +92 42 35709868

Shop No. 3, 50-Civic Centre
Moon Market, Gulshan-e-Ravi
Lahore
CC 50
Tel: +92 42 37466070

462 – Main Boulevard
Shadman
Near Fatima Memorial Hospital
Lahore
CC 51
Tel: +92 42 35960462
Fax: +92 4237567082

115 – G/1, Johar Town
Lahore

CC 55
Tel: +92 42 35290858
Fax: +92 42 35290858

Shop No. 54, A-Block Market
Model Town
Lahore
CC 56
Tel: +92 42 35881892
Fax: +92 42 35881892

Shop No. 543/4, Block-E
Punjab Cooperative Housing
Society
Off. Ghazi Road
Lahore
CC 57
Tel: +92 42 36172668

8-Bagh Ali Road
Near Girja Chowk, Lahore Cantt.
Lahore
CC 59
Tel: +92 42 36667423
Fax: +92 42 36667424

Shop No.1, Ejaz Hospital Building
Mandi Stop, Main Wahdat Road
Lahore
CC 60
Tel: +92 42 35430880
Fax: +92 42 35432615

1 – Km, Raiwind Road
Near Al-Khan Restaurant, Thokar
Niaz Baig
Lahore
CC 63
Tel: +92 42 37498286
Fax: +92 42 37498276

39-Faraz Mahmood Plaza
Commercial Lane
Cavalary Ground
Lahore
CC 65
Tel: +92 42 36610166
Fax: +92 42 36610153

Shop No 5-A, Queens Road
Near Sir Ganga Ram Hospital
Lahore
CC 90
Tel: +92 42 3637 5588
Fax: +92 42 3637 3449

274, Block – C, Al-Faisal Town
Near NC Police Post,
Bahar Shah Road
Lahore Cantt, Lahore

CC 89
Tel: +92 42 36632962
Fax: +92 42 36610153

7-A1 P&D Housing Society Phase-1
Main Canal Road
Lahore
CC 94
Tel: +92 300 0855473

Shop# 14, D-1 Plaza Shaheen
Block Sector B, Bahria Town,
Lahore
CC 94-A
Tel: +92 42 3534 1024

Shop No. 3, 37 Civic Centre
Barkat Market, Garden Town,
Lahore
CC 95
Tel: +92 42 3583 7398
Fax: +92 42 3583 7398

Plaza No. 62, Near Jalal Sons
CCA, Phase-5, DHA
Lahore
CC 100
Tel: +92 42 37182206
Fax: +92 42 37182207

3 Main GT Road
Madina Colony
Shahdara, Lahore
CC 102
Tel: +92 42 37929991

6-A Shalimar Link Road
Lahore
CC 103
Tel: +92 42 36823451
Fax: +92 42 36823452

Shop 7B-111, Main Boulevard
Punjab Govt. Employees
Cooperative Housing Society
Opposite Umer Cash and Carry
Lahore
Tel: +92 42 35181726

Shop No. 51-A, Muhafiz Town
Adjacent HBL, Near EME Main
Canal Road
Lahore
CC 124
+92 42 35457665

Near Dawn Bread Factory
Opposite Taj Bagh Pull, Harbans
Pura
Lahore Cantt., Lahore

CC 125
+92 42 37161228

Shop No 1, Opposite LMDC
Main Canal Road
Lahore
CC 130
Tel: +92 42 37392525

Shop no. 1, E-178/2, Street 5
Near Hajvery Milk Shop
Bhatta Kohar, New Airport Road
Lahore
CC 142
Tel: +92 42 37397333-32

10-B-XX, Khayaban-e-Iqbal, DHA
Lahore
CC 144
Tel: +92 42 35693937

Shop C-3, Block D Commercial Area
Valancia Housing Society
Lahore
CC 146
Tel: +92 42 35225883

Shop # 19, Al Murtaza Market
Near Ittefaq Hospital, Model Town
Lahore
CC 151
Tel: +92 042 35918433

Shop No. 12-B, Johar Town
Near Allah Hoo Chwok
Lahore
CC 152
Tel: +92 042-35170801

Pak Arab Society
Main Ferozpur Road
Lahore
CC 157
Tel: +92 42 35922935

Shop No. 6, 39-Main Market
Karim Block
Allama Iqbal Town
Lahore
CC 154
Tel: +92 42 35415500

Opposite The Educators School
Near Gate No. 1, Paragon City
Barki Road, Lahore
CC 164
Tel: +92 42 37167222

Shop No. 1110/156
Sher Shah Road New Shadbagh
Lahore

CC 170
Tel: +92 42 37605656

Shop No. 1, Ghausia Market
Near Attotck Petrol Pump
Main G.T. Road, Daroghawala
Lahore
Tel: +92 42 36552500

COSMOS 65-D, Muslim Town
Lahore
Tel: +92 42 35912389

Shop No. 08 Lane No. 14 Askari V
Walton, Gulberg-3
Lahore
CC 21-A
Tel: +92 42 3585352

Hasnain Medical Complex
7 – Noon Avenue
Old Muslim Town
Lahore
Tel: +92 42 35914581

Shop No. 5, Rehmat Ali Market
Adjacent to Zong Frenchise
23 km Main Ferozpur Road,
Kahna Nau
Lahore
CC 201
Tel: +92 42 35273722

59 Main Alamgir Road
Islampura, Krishan Nagar
Lahore
CC 202
Tel: +92 42 37153441

Shop No. 3&4 Opposite Rural
Health Centre
Aadil Town Manga Mandi
Lahore
CC 208
Tel: +92 42 35383857-35383858

50-G, Phase 1
DHA, Lahore
CC 214
Tel: 042-35742272-35742273

Plaza No. 125 CCA, DD- Block
Phase-4, DHA
Lahore
CC 215
Tel: 0316-8142349

Lala Musa

Railway Road
Lala Musa

CC 121-A
Tel: +92 53 7518090

Layyah

Shop No. 40 Ghalla Mandi
Link Road, Opp. DHQ Hospital
Layyah
CC 71
Tel: +92 606 410151
Fax: +92 606 410152

Mandi Bahauddin

Shop No. 1, Rajpoot Market
Near Cheema Chowk, Jail Road
Mandi Bahauddin
CC 72
Tel: +92 546 600351
Fax: +92 546 600352

Mardan

Umer Medical Centre, Shamsi Road
Mardan
CC 32
Tel: +92 937 876099
Fax: +92 937 876099

Basreen Plaza
Opposite Mardan Medical Complex
Mardan
CC 32-A
Tel: +92 937 844737

Mianwali

Shop No. 1, Jawad Plaza
Gulberg Chowk
Mianwali
CC 110
Tel: +92 459 234157
Fax: +92 459 234158

Mian Channu

Shop No. 57, Gulshan-e-Ahmad
Talamba Road, Opposite Girls
College
Mian Channu
CC 81-A
Tel: +92 65 2663865

Mirpur

Opposite Awami Marriage Hall
Mirpur, Azad Kashmir
CC 52
Tel: +92 5827446412
Fax: +92 5827446412

Multan

CC 37 A. Quide Azam Road opp.
Mall Plaza Multan Cantt

CC 70. Gulgasht Colony, Tehsil
Chowk, Main Bosan Road,

CC 70 A. Shop #15 D Northern
Bypass Wapda Town

Shop No. 16 – 17
Dost Medical Complex
Near Nishtar Hospital, Nisthar
Road.

Multan
CC 37
Tel: +92 61 4549050
Fax: +92 61 4549060

Near Fatima Hospital, Chowk
Rasheedabad
Khanewal Road
Multan
CC 107
Tel: +92 61 6305881

Shop # 01, near Science School
Z – Block, Gulshan Market
Multan
CC 107-A
Tel: +92 61 6774881

Muridky

Near Dar-e- Arkum School
Mohallah Ahmadpura, G.T. Road
Murdiky
CC 169
Tel: + 92 42 37980555

Muzaffarabad

Shop No. 1 & 2, Lower Plate
Ward No. 10, Neelum Valley Road
Muzaffarabad.
CC 212
Tel: 0316-4814644/05822-207087

Muzaffargarh

CC 219. Shop#1, Bhutta Market, Opp
D.H.Q hospital, Ali Pur road
Muzaffargarh
CC 104
Tel: +92 66 2425243

Nowshera

Shop No. 1, Zarifullah Khan Plaza

Near D.H.Q. Hospital,
Hospital Road
Nowshera
CC 73
Tel: 0923-645112
Fax: 0923-645113

Okara

64-Waris Colony, Tehsil Road
Opp. Education Office
Okara
CC 64
Tel: +92 44 2528786
Fax: +92 44 2551386

Pakpattan

College Road, Near Tanveer
Hospital
Pakpattan
CC 83
Tel: +92 457 371168

Pattoki

Shop No. 1, Ghazi Plaza
Faisal Colony
Pattoki
CC 117
+92 49 4424045

Peshawar

G – 81/82, Auqaf Plaza
Dabgari Gardens
Peshawar
CC 5
Tel: +92 91 2561401
Fax: +92 91 2567644

Shop No. 14
Doctor Plaza, Opposite Hayyatabad
Medical Complex, Hayyatabad
Peshawar
CC 30
Tel: +92 91 5823545
Fax: +92 91 5823545

Shop No. 3, Saddiquil Mansion, Near
Amin Hotel
Hashtnagri G.T Road
Peshawar
CC 42
Tel: +92 91 258 1801
Fax: +92 91 258 1802

29 The Mall Near First Women bank
Opposite FG Degree College for
Women

Peshawar Cantt.
CC 42-A
Tel: +92 91 5284114

Shop No. 6, Amir Market
Opposite Government Hostel
Khyber Teaching Hospital,
University Town
Peshawar
CC 49
Tel: +92 91 6011799
Fax: +92 91 5102738

Shop No 5, Emergency Gate
Lady Reading Hospital Road
Peshawar

CC 74
Tel: +92 91 2567609
Fax: +92 91 2567619

Pirmahal

City Plaza, Sahib-e-Lolak Chowk
Masjid Block
Pir Mahal
CC 140
Tel: +92 46 336 6686

Qila Didar Singh

CC 145 A Near Alkhidmat Hospital
Main Hafizabad Road,

Quetta

Shop No. 1-2, Hotel Marina
Quwari Road, Corner Jinnah Road
Quetta
CC 41
Tel: +92 81 2822977
Fax: +92 81 2869049

Jilani Khan Road,
Satellite Town,
Quetta
CC 41-A
Tel: +92 81 2448577

Alamdard Road Corner Wafa Road,
Quetta.
CC 41-B
Tel: +92 81 2835136

Rahim Yar Khan

4 – Sheikh Zayed Hospital Road
Rahim Yar Khan
CC 155
Tel: +92 68 5886591

Fax: +92 68 5886591

Plot No. 14-15, Shop No. 1
Businessman Colony
Rahim Yar Khan
CC 158
Tel: +92 68 5870700

Rajanpur

CC 80 Shop no. 02 Khan Plaza, Near
D.H.Q. Hospital,

Rawalpindi

Shop No. NW-713
Saidpur Road
Rawalpindi
CC 126
Tel: +92 51 4570447
Fax: +92 51 4429348

Shop No 35-D, Opposite to F.G
School
Near Shell Petrol Pump, Haider
Road
Saddar Cantt, Rawalpindi
CC 84
Tel: +92 51 5701300

Sadiqabad

Opposite National Ice Factory,
Hospital Road
Sadiqabad
CC 156
Tel: +92 68 580 2996

Sahiwal

Liaqat Road, Opp. Govt. Commerce
College
Near Fiveway Chowk
Sahiwal
CC 6
Tel: +92 40 4228881
Fax: +92 40 4554334

Shop No. 106, Near Jamia
Rasheedia
Pakpatan Chowk
Sahiwal
CC 166
Tel: +92 40 4403570

Sambrial

Naik Pura, G.T. Road
Sambrial.
CC 113-A

Tel: +92 52 6523030

Sargodha

71-A, Main Bazar Road
Satellite Town
Sargodha.
CC 16
Tel: +92 48 3222013
Fax: +92 48 3222257

Shop No. 1, Azeem Building
Opposite Chen One Tower
University Road
Sargodha
CC 153
Tel: +92 48 3217070

Sheikhupura

Civic Centre
Near Trauma Centre D.H.Q. Hospital
Sheikhupura
CC 75
Tel: +92 56 3781234

Centre Point Plaza
Bypass Road
Sheikhupura
CC 160
Tel: +92 56 3792850

Sialkot

16 – Cantonment Plaza
Allama Iqbal Road
Sialkot Cantt., Sialkot.
CC 12
Tel: +92 52 4581827
Fax: +92 52 4587378

Shop No. 2/R-H, Alam Chowk
Sialkot
CC 106
Tel: + 92 52 3241382
Fax: +92 52 3251382

Adjacent to Track of Surgical
Main Commissioner Road
Near Lalazar Chowk
Sialkot
CC 172
Tel: +92 52 4581101

Sumandari

Opposite Bank Alfalah
Near Ghalla Mandi, Gojra Road
Sumandari
CC 137

Tel: +92 413 424517

Swabi

Shop No. 1, Near Sehat Medical
Centre
Jahangira Road
Swabi
CC 79
Tel: +92 938 221099
Fax: +92 938 221098

Swat

Near police Station Saidu Sharif
Opposite Saidu Hospital
Swat
CC 33
Tel: +92 946 714407

Takht Bai

Opposite Railway Station
Malakand Road
Takht Bai.
CC 79-A
Tel: +92 937 551333

Taunsa

CC 31A
Vohra Road opp. MCB

Temergara

Abbasi Medical Centre
Opposite DHQ Hospital
District Lower, Temergara
CC 38
Tel: +92 945 620460
Fax: +92 945 824525

Toba Tek Singh

Shop No. 57, Opposite District
Courts
Main Rajana Road
Toba Tek Singh
CC 109
Tel: +92 46 2517 322

Upper Dir

Opposite Police Station Main Dir
Chirtal Road
Dir Town, Upper Dir
CC 165
Tel: +92 0944 880765

Vehari

Jinnah Road, H Block
Opposite Sadar Police Station
Vehari.
CC 213
Tel: +92 67 3365000

Wah Cantt

Shop No. 10, Cantt. Board Market
Mall Road
Wah Cantt.
CC 141
Tel: +92 51 453 3062

Wazirabad

Allah Wala Chowk, Purani Sabzi
Mandi
Near Gourmet Bakers, G.T Road
Wazirabad
CC 113
Tel: +92 55 6605830



Shaukat Khanum Memorial Cancer Hospital and Research Centre

7A Block R-3, M.A. Johar Town, Lahore

Tel: +92 42 3590 5000 | Fax: +92 42 3594 5208 | UAN: 111 155 555 | Toll-free: 0800 11555

www.shaukatkhanum.org.pk